
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

			FORM 10-Q

(Mark one)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2023~~2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39452



INHIBRX, INC.

(Exact name of registrant as specified in its charter)

Delaware		82-4257312
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

11025 N. Torrey Pines Road, Suite 200
La Jolla, California		92037
(Address of principal executive offices)		(Zip Code)

	(858) 795-4220
(Registrant’s telephone number, including area code)

	N/A
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001

INBX

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐☒ Accelerated filer ☐ Non-accelerated filer ☒☐ Smaller reporting company ☒☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~October~~April 3130, ~~2023~~2024, the registrant had 4752,~~290~~401,~~666~~941 shares of common stock outstanding.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or this Quarterly Report, contains express and implied forward-looking statements that involve risks and uncertainties. Except as otherwise indicated by the context, references in this Quarterly Report to “we,” “us” and “our” are to the consolidated business of Inhibrx, Inc., or the Company, or Inhibrx. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “possible,” “potential,” “predict,” “project,” “design,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

•our ability to complete the Merger (as defined below) and related spin-out transaction (as described below);

•the initiation, timing, progress and results of our research and development programs as well as our preclinical studies and clinical trials;

•our ability to advance therapeutic candidates into, and successfully complete, clinical trials;

•our interpretation of initial, interim or preliminary data from our clinical trials, including interpretations regarding disease control and disease response;

•the timing or likelihood of regulatory filings and approvals;

•the commercialization of our therapeutic candidates, if approved;

•the pricing, coverage and reimbursement of our therapeutic candidates, if approved;

•our ability to utilize our technology platform to generate and advance additional therapeutic candidates;

•the implementation of our business model and strategic plans for our business and therapeutic candidates;

•our ability to successfully manufacture our therapeutic candidates for clinical trials and commercial use, if approved;

•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

•the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates;

•our ability to enter into strategic partnerships and the potential benefits of such partnerships;

•our estimates regarding expenses, capital requirements and needs for additional financing;

•our ability to raise funds needed to satisfy our capital requirements, which may depend on financial, economic and market conditions and other factors, over which we may have no or limited control;

•our and our third-party partners’ and service providers’ ability to continue operations and advance our therapeutic candidates through clinical trials, as well as the ability of our third party manufacturers to provide the required raw materials, antibodies and other biologics for our preclinical research and clinical trials, in light of the current market conditions or any pandemics, regional conflicts, sanctions, labor conditions, ~~and~~ geopolitical events, natural disasters or extreme weather events;

•our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; and

•developments relating to our competitors and our industry.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2022~~2023, filed with the Securities and Exchange Commission, or the SEC, on ~~March~~February 628, ~~2023, and as updated in our Quarterly Report on Form 10-Q for the three months ended March 31, 2023, filed with the SEC on May 8, 2023~~2024. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or ~~incomplete, and our statements should not be read to indicate that we have conducted an exhaustive~~

incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to new information, actual results or to changes in our expectations, except as required by law.

You should read this Quarterly Report and the documents that we file with the SEC with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

This Quarterly Report includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Quarterly Report appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.

TABLE OF CONTENTS

		Page
	Part I. Financial Information
Item 1.	Financial Statements (unaudited)
	Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022	4
	Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023	4
	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and September 30, 2022	5
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and March 31, 2023	5
	Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2023 and September 30, 2022	6
	Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2024 and March 31, 2023	6
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and September 30, 2022	8
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and March 31, 2023	7
	Notes to the Condensed Consolidated Financial Statements	108
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2421
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	3934
Item 4.	Controls and Procedures	4035
	Part II. Other Information
Item 1.	Legal Proceedings	4136
Item 1A.	Risk Factors	4136
Item 2.	Unregistered Sales of Equity Securities, ~~Use of Proceeds~~ and ~~Issuer~~Use ~~Purchase~~ of ~~Equity Securities~~Proceeds	4136
Item 3.	Defaults Upon Senior Securities	4136
Item 4.	Mine Safety Disclosures	4136
Item 5.	Other Information	4136
Item 6.	Exhibits	4237
	Signatures	4338

Part I — Financial Information

Item 1. Financial Statements.

Inhibrx, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share data and par value)
(Unaudited)

	SEPTEMBER 30,		DECEMBER 31,
	MARCH 31,		DECEMBER 31,
	2023		2022
	2024		2023
Assets
Current assets:
Cash and cash equivalents	$	~~337~~252,~~327~~483	$	~~273~~277,~~865~~924
Accounts receivable	~~331~~171		~~243~~171
Receivables from related parties	—		14
Other receivables	2,867		607
Prepaid expenses and other current assets	2519,~~639~~017		616,~~371~~656
Total current assets	~~363~~274,~~297~~538		~~280~~295,~~493~~358
Property and equipment, net	26,~~864~~966		26,~~501~~419
Operating right-of-use asset	32,~~408~~487		42,~~717~~952
Other non-current assets	34,~~164~~586		3,164
Total assets	$	~~372~~288,~~733~~577	$	~~290~~307,~~875~~893
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	714,~~858~~792	$	810,~~326~~954
Accrued expenses	2551,~~902~~329		1743,~~224~~295
Deferred revenue	—		166
Current portion of long-term debt, net of discount	3,632		—
Current portion of operating lease liability	2,~~011~~117		12,~~860~~063
Total current liabilities	3571,~~771~~870		2756,~~576~~312
Long-term debt, including final payment fee	~~205~~204,~~721~~578		~~202~~206,~~069~~968
Non-current portion of operating lease liability	~~1,646~~561		31,~~173~~110
Total liabilities	~~243~~277,~~138~~009		~~232~~264,~~818~~390
Commitments and contingencies (Note 8)
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value; 15,000,000 shares authorized as of September 30, 2023 and December 31, 2022; no shares issued or outstanding as of September 30, 2023 and December 31, 2022.	—		—
Preferred stock, $0.0001 par value; 15,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023.	—		—
Common stock, $0.0001 par value; 120,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 47,290,666 and 43,564,283 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively.	5		4
Common stock, $0.0001 par value; 120,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 49,234,225 and 47,369,511 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	5		5
Additional paid-in-capital	~~649~~704,~~720~~007		~~430~~657,~~426~~232
Accumulated deficit	(~~520~~692,~~130~~444)		(~~372~~613,~~373~~734)
Total stockholders’ equity	~~129~~11,~~595~~568		5843,~~057~~503
Total liabilities and stockholders’ equity	$	~~372~~288,~~733~~577	$	~~290~~307,~~875~~893

The accompanying notes are an integral part of these condensed consolidated financial statements.

Inhibrx, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)

THREE MONTHS ENDEDSEPTEMBER 30,

NINE MONTHS ENDEDSEPTEMBER 30,

THREE MONTHS ENDEDMARCH 31,

2023

2022

2023

2022

2024

2023

Revenue:

License fee revenue

~~119~~—

~~278~~17

~~166~~

~~1,904~~

Grant revenue

—

Total revenue

—

Total revenue

119

278

166

1,918

Operating expenses:

Research and development

3863,~~057~~851

2437,~~934~~386

~~109,549~~

~~79,735~~

General and administrative

79,~~889~~974

56,~~347~~397

~~21,549~~

~~15,800~~

Total operating expenses

4573,~~946~~825

3043,~~281~~783

~~131,098~~

~~95,535~~

Loss from operations

(4573,~~827~~825)

(3043,~~003~~766)

~~(130,932)~~

~~(93,617)~~

Other income (expense):

Interest expense

(8,~~149~~130)

(57,~~547~~563)

~~(23,617)~~

~~(11,067)~~

Interest income

23,~~324~~304

~~207~~2,483

~~7,221~~

~~305~~

Other income (expense), net

(135)

(422)

Other expense, net

(59)

(70)

Total other expense

(54,~~960~~885)

(5,~~322~~150)

~~(16,818)~~

~~(10,690)~~

Loss before income tax expense

(5178,~~787~~710)

(3548,~~325~~916)

~~(147,750)~~

~~(104,307)~~

Provision for income taxes

2—

—

Net loss

(5178,~~789~~710)

(3548,~~325~~916)

~~(147,757)~~

~~(104,311)~~

Net loss per share, basic and diluted

(1.1044)

(01.9012)

~~(3.30)~~

~~(2.67)~~

Weighted-average shares of common stock and pre-funded warrants outstanding, basic and diluted

4754,~~151~~554

3943,~~071~~575

~~44,803~~

~~39,043~~

The accompanying notes are an integral part of these condensed consolidated financial statements.

Inhibrx, Inc.Condensed Consolidated Statements of Stockholders’ Equity (~~Deficit)(~~In thousands)(Unaudited)

	Common Stock(Shares)	Common Stock(Amount)		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity ~~(Deficit)~~
Balance as of December 31, 2022	43,564	$	4	$	430,426	$	(372,373)	$	58,057
Balance as of December 31, 2023	47,369	$	5	$	657,232	$	(613,734)	$	43,503
Stock-based compensation expense	—	—		56,~~636~~397		—		56,~~636~~397
Issuance of shares upon exercise of stock options	311,865	—		~~356~~40,378		—		~~356~~40,378
Net loss	—	—		—		(4878,~~916~~710)		(4878,~~916~~710)
Balance as of March 31, 2023	43,595	$	4	$	436,418	$	(421,289)	$	15,133
Balance as of March 31, 2024	49,234	$	5	$	704,007	$	(692,444)	$	11,568
Stock-based compensation expense	—	—		6,253		—		6,253
Issuance of shares upon exercise of stock options	72	—		854		—		854
Net loss	—	—		—		(47,052)		(47,052)
Balance as of June 30, 2023	43,667	$	4	$	443,525	$	(468,341)	$	(24,812)
Stock-based compensation expense	—	—		6,530		—		6,530
Issuance of shares upon exercise of stock options	2	—		21		—		21
Issuance of common stock and pre-funded warrants in private placement, net of issuance costs	3,621	1		199,644		—		199,645
Net loss	—	—		—		(51,789)		(51,789)
Balance as of September 30, 2023	47,290	$	5	$	649,720	$	(520,130)	$	129,595


	Common Stock (Shares)	Common Stock (Amount)		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity
Balance as of December 31, 2022	43,564	$	4	$	430,426	$	(372,373)	$	58,057
Stock-based compensation expense	—	—		5,636		—		5,636
Issuance of shares upon exercise of stock options	31	—		356		—		356
Net loss	—	—		—		(48,916)		(48,916)
Balance as of March 31, 2023	43,595	$	4	$	436,418	$	(421,289)	$	15,133

	Common Stock(Shares)	Common Stock (Amount)		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity (Deficit)
Balance as of December 31, 2021	38,991	$	4	$	279,526	$	(227,147)	$	52,383
Stock-based compensation expense	—	—		5,108		—		5,108
Issuance of shares upon exercise of stock options	35	—		401		—		401
Issuance of warrants	—	—		712		—		712
Net loss	—	—		—		(31,254)		(31,254)
Balance as of March 31, 2022	39,026	$	4	$	285,747	$	(258,401)	$	27,350
Stock-based compensation expense	—	—		5,296		—		5,296
Issuance of shares upon exercise of stock options	15	—		164		—		164
Net loss	—	—		—		(37,732)		(37,732)
Balance as of June 30, 2022	39,041	$	4	$	291,207	$	(296,133)	$	(4,922)
Stock-based compensation expense	—	—		4,691		—		4,691
Issuance of shares upon exercise of stock options	45	—		506		—		506
Net loss	—	—		—		(35,325)		(35,325)
Balance as of September 30, 2022	39,086	$	4	$	296,404	$	(331,458)	$	(35,050)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Inhibrx, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)

(Unaudited)

	NINE MONTHS ENDEDSEPTEMBER 30,
	THREE MONTHS ENDEDMARCH 31,
	2023		2022
	2024		2023
Cash flows from operating activities
Net loss	$	(~~147~~78,~~757~~710)	$	(~~104~~48,~~311~~916)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	~~893~~360		~~923~~295
Accretion of debt discount and non-cash interest expense	31,~~652~~242		21,~~190~~196
Stock-based compensation expense	186,~~419~~397		155,~~095~~636
Non-cash lease expense	~~1,309~~465		~~1,203~~427
Loss on disposal of fixed assets	3—		182
Changes in operating assets and liabilities:
Accounts receivable	~~(88)~~—		~~130~~(61)
Receivables from related parties	14		433
Other receivables	(610)		—
Prepaid expenses and other current assets	(19,268)		(383)
Receivables from related parties	—		14
Other non-current assets	—		(1,317)
Prepaid expenses and other current assets	(2,361)		(2,848)
Accounts payable	(801)		(724)
Other non-current assets	(1,422)		—
Accrued expenses	8,678		4,984
Accounts payable	4,050		2,332
Operating lease liability	(1,376)		(1,238)
Accrued expenses	8,034		2,442
Deferred revenue, current portion	(166)		(1,594)
Operating lease liability	(495)		(446)
Deferred revenue, non-current portion	—		(110)
Deferred revenue, current portion	—		(17)
Net cash used in operating activities	(~~136~~63,~~488~~050)		(8439,~~701~~944)
Cash flows from investing activities
Purchase of fixed assets	(1,~~151~~119)		(~~419~~23)
Net cash used in investing activities	(1,~~151~~119)		(~~419~~23)
Cash flows from financing activities
Proceeds from issuance of common stock and pre-funded warrants in private placement	200,000		—
Proceeds from the exercise of stock options	38,728		356
Issuance costs associated with issuance of common stock and pre-funded warrants in private placement	(130)		—
Net cash provided by financing activities	38,728		356
Proceeds from the issuance of debt	—		98,871
Net decrease in cash and cash equivalents	(25,441)		(39,611)
Payment of fees associated with debt	—		(50)
Cash and cash equivalents at beginning of period	277,924		273,865
Proceeds from the exercise of stock options	1,231		1,071
Cash and cash equivalents at end of period	$	252,483	$	234,254
Net cash provided by financing activities	201,101		99,892
Supplemental schedule of non-cash investing and financing activities
Net increase in cash and cash equivalents	63,462		14,772
Payable for purchase of fixed assets	$	307	$	258
Cash and cash equivalents at beginning of period	273,865		131,301
Receivable for proceeds from the exercise of stock options	$	1,650	$	—
Cash and cash equivalents at end of period	$	337,327	$	146,073

Supplemental schedule of non-cash investing and financing activities
Payable for purchase of fixed assets	$	108	$	261
Issuance costs associated with the issuance of common stock and pre-funded warrants in private placement in accounts payable	$	225	$	—
Fair value of warrants issued to lender in conjunction with February 2022 Amendment (as defined in Note 3)	$	—	$	712

The accompanying notes are an integral part of these condensed consolidated financial statements.

Inhibrx, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

Inhibrx, Inc., or the Company, or Inhibrx, is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company’s current pipeline is focused on oncology and orphan diseases.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an interim report on the Form 10-Q. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

The unaudited interim condensed consolidated financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited interim condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods.

Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the fiscal year ended December 31, ~~2022~~2023, which are included in the Company’s Annual Report on Form 10-K filed with the SEC on ~~March~~February 628, ~~2023~~2024.

Reclassification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

Merger and Spin-Off

On January 22, 2024, the Company, Aventis Inc., or Parent, a wholly owned indirect subsidiary of Sanofi, and Art Acquisition Sub, Inc., or the Merger Sub, a wholly owned subsidiary of Parent, entered into an Agreement and Plan of Merger, or the Merger Agreement. Pursuant to the terms of the Merger Agreement, Parent will acquire all outstanding shares of the Company via the merger of Merger Sub with and into the Company, or Merger, with the Company surviving the Merger as a wholly owned subsidiary of Parent, and in turn each shareholder will receive (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx Biosciences, Inc., or New Inhibrx, for every four shares of Inhibrx common stock held. In addition, in connection with the transaction, Parent will (1) assume and retire the Company’s outstanding third-party debt, (2) cause New Inhibrx to be funded with $200.0 million in cash, and (3) retain an equity interest in New Inhibrx of approximately 8%.

In connection with and as a condition to the Merger, the Company and New Inhibrx entered into a Separation and Distribution Agreement, dated as of January 22, 2024, or the Separation and Distribution Agreement, pursuant to which, immediately prior to the effective time of the Merger: (i) the Company will effect a pre-closing reorganization, which will result in (x) the Company owning, assuming or retaining all assets and liabilities primarily related to INBRX-101, or the 101 Business, and (y) New Inhibrx owning, assuming or retaining all other assets and liabilities of the Company and its subsidiaries; and (ii) thereafter, the Company will distribute to its stockholders as of the record date on a pro rata basis, 92% of the issued and outstanding shares of New Inhibrx common stock, at a ratio of one share of New Inhibrx common stock for every four shares of the Company’s issued and outstanding common stock held on the record date. Following the spin-off, New Inhibrx will be a separate

public company and the Company will retain 8% of the issued and outstanding shares of New Inhibrx common stock as of the effective time of the spin-off.

The boards of directors of both the Company and Sanofi have unanimously approved the spin-off and the Merger. Parent will pay transaction consideration totaling approximately $2.2 billion in aggregate value. Parent will also make payments at the closing of the Merger to settle the Company’s third-party debt. Following the closing of the Merger, New Inhibrx will continue to operate under the Inhibrx name. Parent’s acquisition of the Company is subject to the completion of the New Inhibrx spin-off transaction and other customary closing conditions, including approval by the Company’s shareholders. The companies expect the transaction to close in the second quarter of 2024.

The Merger Agreement contains certain termination rights for each of the Company and Parent. Upon termination of the Merger Agreement in accordance with its terms, under certain circumstances, the Company will be required to pay Parent a termination fee in an amount equal to $54.5 million, including if the Merger Agreement is terminated due to (i) the Company accepting a Superior Proposal (as defined in the Merger Agreement) or (ii) the board of directors changing its recommendation that stockholders vote to approve the Merger Agreement. This termination fee will also be payable by the Company if the Merger Agreement is terminated under certain circumstances and prior to such termination, a proposal to acquire the 101 Business or more than 50% of the Company’s stock or assets is made or publicly announced and not publicly withdrawn and the Company enters into a definitive agreement for, or completes, any transaction involving the acquisition of the 101 Business or more than 50% of its stock or assets within twelve months of such termination. The Merger Agreement also provided that Parent will be required to pay the Company a reverse termination fee of $92.1 million if the Merger is not consummated due to the failure of certain conditions to be satisfied as a result of failure to obtain antitrust clearance. The Company and Parent filed notification of the proposed Merger with the Federal Trade Commission and the Department of Justice under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or the HSR Act. The applicable waiting period under the HSR Act expired on March 11, 2024.

Liquidity

As of ~~September~~March 3031, ~~2023~~2024, the Company had an accumulated deficit of $~~520~~692.14 million and cash and cash equivalents of $~~337~~252.35 million. From its inception and through ~~September~~March 3031, ~~2023~~2024, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities.

In August 2023, the Company received gross proceeds of $200.0 million before deducting $0.4 million of offering expenses payable by the Company in a private placement transaction, or the Private Placement, with certain institutional and other accredited investors, or Purchasers, in which the Company sold and issued 3,621,314 shares of the Company’s common stock and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock. See Note 4 for further discussion of this equity offering.

The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company’s operations for at least 12 months from the date these condensed consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements.

If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders’ rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and

109

development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.

The rules and regulations of the SEC or any other regulatory agencies may restrict the Company’s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.

Use of Estimates

The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The Company’s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company’s operating lease, and valuation allowances for the Company’s deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The Company’s actual results may differ from these estimates under different assumptions or conditions.

Cash and Cash Equivalents

Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep, and money market accounts~~, and highly liquid investments in debt securities with an original maturity of three months or less~~. ~~The Company’s investments in debt securities have consisted of U.S. Treasury Bills, which were recorded at their amortized cost, reflective of the amortization or accretion of premiums or discounts.~~

As of September 30, 2023, the Company held no investments in debt securities. As of December 31, 2022, the Company held investments in debt securities of $196.3 million.

Concentrations of Credit Risk

Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or FDIC, of up to $250,000. The Company’s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.

Fair Value Measurements

The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include:

•Level 1 - Quoted prices in active markets for identical assets or liabilities.

•Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

During the nine months ended September 30, 2023, the Company’s investments in debt securities consisted of U.S. Treasury Bills, which were classified as Level 1 in the fair value hierarchy. Due to the short-term nature of these securities which were classified as cash equivalents, the amortized value approximated fair value and the Company did not remeasure these instruments at fair value. As of September 30, 2023, the Company held no investments in debt securities following their maturity during the three months ended September 30, 2023. The Company’s outstanding debt is classified as Level 2 in the fair value hierarchy. As of September 30, 2023 and December 31, 2022, the Company had no financial instruments measured at fair value on a recurring basis.10

~~Revenue~~During ~~Recognition~~the three months ended March 31, 2023, the Company’s investments in debt securities consisted of U.S. Treasury Bills, which were classified as Level 1 in the fair value hierarchy. Due to the short-term nature of these securities which were classified as cash equivalents, the amortized value approximated fair value and the Company did not remeasure these instruments at fair value. As of March 31, 2024 and December 31, 2023, the Company held no investments in debt securities. The Company’s outstanding debt is classified as Level 2 in the fair value hierarchy. As of March 31, 2024 and December 31, 2023, the Company had no financial instruments measured at fair value on a recurring basis.

The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.

Collaborative Research, Development, and License Agreements

The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license and the performance of research and development activities. The terms associated with these agreements may include one or more of the following: (1) license fees; (2) nonrefundable up-front fees; (3) payments for reimbursement of research costs; (4) payments associated with achieving specific development, regulatory or commercial milestones; and (5) royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the condensed consolidated balance sheet, until all revenue recognition criteria are met.

Typically, license fees, non-refundable upfront fees and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs.

The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company’s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.

Accrued Research and Development and Clinical Trial Costs

Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place. The Company’s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company’s purchases of in-process research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.

expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CDMOs. The Company’s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. Costs incurred related to the Company’s purchases of in-process research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common stock ~~equivalent~~equivalents outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive.

The weighted average number of common stock used in the basic and diluted net loss per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.

For purposes of the diluted net loss per share calculation, ~~warrants for purchase of common stock,~~ other than pre-funded warrants as discussed above, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Accordingly, for the ~~nine~~three months ended ~~September~~March 3031, ~~2023~~2024 and ~~September~~March 3031, ~~2022~~2023, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.

	THREE MONTHS ENDEDSEPTEMBER 30,		NINE MONTHS ENDEDSEPTEMBER 30,
	2023	2022	2023	2022
Outstanding stock options	6,650	5,229	6,269	4,925
Warrants to purchase common stock	47	47	47	40
	6,697	5,276	6,316	4,965

Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, as weighted based on the period outstanding, are as follows (in thousands):


	THREE MONTHS ENDED MARCH 31,
	2024	2023

Outstanding stock options	6,042	5,785

Warrants to purchase common stock	47	47
Total	6,089	5,832

Segment Information

The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its condensed consolidated financial condition or results of operations upon adoption.

13Recently Issued but Not Yet Adopted Accounting Pronouncements

~~Adoption~~In ofNovember ~~New~~2023, the FASB issued Accounting ~~Pronouncements~~Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this ASU to determine its impact on the Company's consolidated financial statements and related disclosures.

In ~~June~~December ~~2016~~2023, the FASB issued ~~Accounting Standards Update, or~~ ASU, ~~2016~~2023-1309, ~~Financial~~ ~~Instruments~~Income -Taxes ~~Credit~~(Topic ~~Losses~~740): ~~Measurement~~Improvement ofto ~~Credit~~Income ~~Losses~~Tax onDisclosures ~~Financial~~to ~~Instruments~~enhance ~~(Topic~~the ~~326),~~transparency ~~which~~and ~~intends~~decision tousefulness ~~improve~~of ~~financial~~income ~~reporting~~tax bydisclosures. ~~requiring~~Two ~~earlier~~primary ~~recognition~~enhancements ofrelated ~~credit~~to ~~losses~~this onASU ~~certain~~include ~~financial~~disaggregating ~~assets,~~existing ~~such~~income astax ~~held-~~disclosures relating to~~-maturity~~ ~~debt~~the ~~securities.~~effective ~~Subsequent~~tax torate ~~the~~reconciliation ~~issuance~~and ofincome taxes paid. ASU ~~2016~~2023-~~13,~~09 ~~the~~is ~~FASB~~effective ~~issued~~for ~~several~~annual ~~additional~~periods ~~ASUs~~beginning toafter ~~clarify~~December ~~implementation guidance~~15, ~~provide~~2024 ~~narrow-scope~~on ~~improvements~~a ~~and~~prospective ~~provide~~basis. ~~additional~~Early ~~disclosure~~adoption ~~guidance~~is permitted. The Company ~~adopted~~is ~~ASU~~currently ~~2016-13~~evaluating asthe impact of ~~January~~this 1,accounting ~~2023,~~standard ~~which~~update ~~did not result in a material impact~~ on ~~its~~the ~~condensed~~Company's consolidated financial statements and related disclosures.

2. OTHER FINANCIAL INFORMATION

Prepaid Expense and Other Current Assets

Prepaid expense and other current assets were comprised of the following (in thousands):

	AS OF		AS OF
	SEPTEMBER 30, 2023		DECEMBER 31, 2022
	MARCH 31, 2024		DECEMBER 31, 2023
Clinical drug substance and product manufacturing (1)	$	188,~~405~~510	~~1,171~~$	9,888
Clinical trials (2)	68,~~015~~372		$5,409	~~4,294~~
Licenses	~~578~~1,044		~~493~~728
Other outside research and development services (3)	305		232
Outside research and development services (3)	552		265
Other	~~336~~539		~~181~~366
Prepaid expense and other current assets	$	2519,~~639~~017	$	616,~~371~~656

(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. ~~As of September 30, 2023, the balance includes a prepayment to one of the Company’s CDMO partners for the purchase of $15.2 million in specialized raw materials with no alternative future use.~~ See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.

(2) Relates primarily to the Company’s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company’s therapeutics. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.

(3) Relates to the Company’s usage of third-parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.

Property and Equipment, Net

Property and equipment, net were comprised of the following (in thousands):

	AS OF		AS OF
	SEPTEMBER 30, 2023		DECEMBER 31, 2022
	MARCH 31, 2024		DECEMBER 31, 2023
Machinery and equipment	$	8,~~073~~519	$	78,~~023~~480
Furniture, fixtures, and other	~~527~~542		~~524~~540
Leasehold improvements	~~441~~795		441
Computer software	53		53
Construction in process	159		—
Construction in process (1)	4,088		3,592
Total property and equipment	913,~~253~~997		813,~~041~~106
Less: accumulated depreciation and amortization	(67,~~389~~031)		(56,~~540~~687)
Property and equipment, net	$	26,~~864~~966	$	26,~~501~~419

~~Depreciation~~(1) ~~and~~Consists ~~amortization expense totaled $0.3 million for each~~ of ~~the~~renovations ~~three~~to ~~months ended September 30, 2023 and September 30, 2022, and $0.9 million for each of~~ the ~~nine~~Company’s ~~months~~office ~~ended~~space ~~September 30, 2023~~ and ~~September 30,~~software ~~2022~~not ~~and~~yet ~~consisted~~placed ~~of the following (~~in ~~thousands):~~service.

14Depreciation and amortization expense totaled $0.4 million and $0.3 million for the three months ended March 31, 2024 and March 31, 2023, respectively, and consisted of the following (in thousands):

	THREE MONTHS ENDEDSEPTEMBER 30,				NINE MONTHS ENDEDSEPTEMBER 30,
	THREE MONTHS ENDEDMARCH 31,
	2023		2022		2023		2022
	2024		2023
Research and development	$	~~261~~256	$	~~251~~237	$	~~740~~	$	~~757~~
General and administrative	43104		58		~~153~~		~~166~~
Total depreciation and amortization expense	$	~~304~~360	$	~~309~~295	$	~~893~~	$	~~923~~

Accrued Expenses

Accrued expenses were comprised of the following (in thousands):

	AS OF		AS OF
	SEPTEMBER 30, 2023		DECEMBER 31, 2022
	MARCH 31, 2024		DECEMBER 31, 2023
Clinical trials(1)	$	7,205	$	4,527
Clinical drug substance and product manufacturing(1)	$	29,912	$	22,805
Clinical drug substance and product manufacturing(2)	5,339		5,381
Clinical trials(2)	14,105		9,224
Compensation-related	5,032		3,374
Other outside research and development (3)	1,144		1,129
Other outside research and development (3)	4,817		1,164
Interest expense	2,344		2,348
Interest expense	2,253		2,124
Compensation-related	2,100		6,506
Professional fees	~~919~~1,318		~~428~~780
Other	~~337~~406		~~226~~503
Accrued expenses	$	2551,~~902~~329	$	1743,~~224~~295

(1) Relates primarily to the Company’s usage of third-party ~~CROs~~CDMOs for ~~management~~clinical ofand ~~clinical~~development ~~trials~~efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.

(2) Relates primarily to the Company’s usage of third-party ~~CDMOs~~CROs for ~~clinical~~management ~~and~~of ~~development~~clinical ~~efforts~~trials. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.

3. DEBT

2020 Loan Agreement

In July 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC, or Oxford~~, pursuant to which it received $10~~.0 ~~million~~Under inthe ~~gross~~original ~~proceeds, or Term A. The~~ 2020 Loan Agreement ~~was~~and ~~subsequently~~subsequent ~~amended~~amendments inbetween November 2020, orand ~~the~~October ~~November 2020 Amendment~~2022, ~~upon which a second tranche in an aggregate principal amount of $20.0 million was funded,~~ or ~~Term B~~collectively, ~~and~~the inAmended ~~June~~2020 ~~2021~~Loan Agreement, or the ~~June~~Company ~~2021~~received ~~Amendment, upon which a third tranche in~~ an aggregate principal amount of $40200.0 million ~~was~~over ~~funded~~seven tranches, or ~~Term~~Terms CA-G.

InThe ~~February 2022, the~~ Company ~~entered~~determined ~~into~~each anof ~~additional amendment, or~~ the ~~February~~amendments ~~2022~~under ~~Amendment, to~~ the ~~2020 Loan Agreement, collectively, the~~ Amended 2020 Loan Agreement, ~~upon~~should ~~which~~be ~~the~~treated ~~Company~~as ~~received~~modifications ~~gross proceeds~~ of ~~$40.0 million,~~the ororiginal ~~Term~~2020 D.Loan ~~The~~Agreement ~~February~~since ~~2022 Amendment also provided for an increase in~~ the ~~interest~~terms ~~rate~~ and ~~for~~resulting ~~three~~cash ~~future~~flows ~~tranches~~were ofnot ~~debt~~substantially tochanged ~~be funded~~ upon ~~the~~each ~~achievement~~ of ~~certain~~the ~~milestones~~amendments. InThe ~~June 2022, the~~ Company ~~received~~has ~~additional~~continued ~~gross~~to ~~proceeds~~amortize ofthe ~~$30.0 million,~~existing ordebt ~~Term~~discounts E,prior ~~following~~to ~~the~~modification ~~initiation~~through ~~of part 4 of~~ the ~~Phase~~Amended ~~1/2~~Maturity ~~clinical~~Date ~~trial of INBRX-105,~~ (as ~~well~~defined ~~as an additional $30~~below).~~0 million in gross proceeds, or Term F, following the receipt of positive topline data from the Phase 1 clinical trial of INBRX-101.~~

In October 2022, the Company entered into an amendment to the Amended 2020 Loan Agreement, or the October 2022 Amendment. The October 2022 Amendment amended the milestone terms of the last remaining tranche, Term G, under the Amended 2020 Loan Agreement to provide for the funding of $30.0 million upon the announcement of the regulatory path for INBRX-101 rather than upon the initiation of a registration-enabling clinical trial of

INBRX-101. In October 2022, the Company met this milestone and drew the final tranche for additional gross proceeds of $30.0 million.

The Company determined the November 2020, June 2021, February 2022, and October 2022 Amendments should be treated as modifications of the original 2020 Loan Agreement since the terms and resulting cash flows were not substantially changed upon each of the amendments. The Company will continue to amortize the existing debt discounts prior to modification through the Amended Maturity Date (as defined below).

As of July 1, 2023, a LIBOR Transition Event, as defined in the Amended 2020 Loan Agreement, occurred, and pursuant to the Amended 2020 Loan Agreement, Oxford selected a LIBOR Replacement Rate, as defined in the Amended 2020 Loan Agreement, replacing the 30 day U.S. Dollar London InterBank Offered Rate with the 1-Month Chicago Mercantile Exchange term secured overnight financing rate, or 1-Month CME Term SOFR, causing an amendment to the interest rate of the Company’s outstanding loans. No other terms were changed. The Company has elected the optional expedient under ASC Topic 848-20 and therefore deemed the modification to not be substantial.

As of ~~September~~March 3031, ~~2023~~2024, the Company had $200.0 million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The outstanding term loans will mature on January 1, 2027, or the Amended Maturity Date, and bear interest at a floating per annum rate equal to the greater of (1) 8.30% or (2) the sum of (i) the 1-Month CME Term SOFR on the last business day of the month that immediately precedes the month in which the interest will accrue, (ii) 0.10%, and (iii) 8.19%. Under the Amended 2020 Loan Agreement, the repayment schedule provides for interest-only payments through February 1, 2025, followed by 23 months of principal and interest payments. In the event of a qualifying financing event in which the Company raises at least $100.0 million in upfront licensing or partnership proceeds by February 2025, the interest-only period may be extended an additional 12 months through February 1, 2026, which would then be followed by 11 months of equal payments of principal plus interest, beginning on March 1, 2026. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. This final payment of $18.0 million is being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending upon the timing of the prepayment.

16Under the Amended 2020 Loan Agreement, the repayment schedule provides for interest-only payments through February 1, 2025, followed by 23 months of principal and interest payments. In the event of a qualifying financing event in which the Company raises at least $100.0 million in upfront licensing or partnership proceeds by February 2025, the interest-only period may be extended an additional 12 months through February 1, 2026, which would then be followed by 11 months of equal payments of principal plus interest, beginning on March 1, 2026. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. This final

~~The Company’s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following as of September 30, 2023 and December 31, 2022 (in thousands).~~14

	AS OF		AS OF
	SEPTEMBER 30, 2023		DECEMBER 31, 2022
Term A	$	10,900	$	10,900
Term B	21,800		21,800
Term C	43,600		43,600
Term D	43,600		43,600
Term E	32,700		32,700
Term F	32,700		32,700
Term G	32,700		32,700
Less: debt discount	(12,279)		(15,931)
Long-term debt, including debt discount and final payment fee	$	205,721	$	202,069

payment of $18.0 million is being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending upon the timing of the prepayment.

AsThe ~~of September 30, 2023, and unless extended in accordance with the terms described above, the~~ Company’s ~~interest-only~~outstanding ~~period~~debt ~~will~~balance ~~continue~~under ~~through~~the ~~February~~Amended ~~2025,~~2020 ~~with~~Loan ~~principal~~Agreement ~~payments~~consisted ~~beginning~~of inthe ~~March~~following ~~2025.~~as ~~Future~~of ~~principal~~March 31, ~~payments~~2024 and ~~final~~December 31, ~~fee~~2023 ~~payments will be made as follows~~ (in thousands):.

	AS OF		AS OF
			SEPTEMBER 30, 2023
	MARCH 31, 2024		DECEMBER 31, 2023
2025			$	86,956
Term A	$	10,900	$	10,900
2026			104,348
Term B	21,800		21,800
2027			26,696
Term C	43,600		43,600
Total future minimum payments			218,000
Term D	43,600		43,600
Less: unamortized debt discount			(12,279)
Term E	32,700		32,700
Total debt			$	205,721
Term F	32,700		32,700
Term G	32,700		32,700
Less: debt discount	(9,790)		(11,032)
Total debt	208,210		206,968
Less: Current portion, including debt discount	(3,632)		—
Long-term debt, including debt discount and final payment fee	$	204,578	$	206,968

~~The~~As ~~Company’s obligations under the Amended 2020 Loan Agreement are secured by a first priority security interest~~ of ~~substantially~~March 31, ~~all of the Company’s assets with a positive lien on intellectual property. The Amended 2020 Loan Agreement includes customary events of default~~2024, ~~including~~and ~~instances~~unless ofextended ~~a material adverse change~~ in ~~the~~accordance ~~Company’s~~with ~~operations, that may require prepayment of~~ the ~~outstanding~~terms ~~term~~described ~~loans. Additionally~~above, ~~following~~ the ~~June 2021 Amendment, the Amended 2020 Loan Agreement requires the~~ Company’s tointerest-only ~~maintain~~period awill ~~minimum~~continue ~~cash~~through ~~balance~~February ~~of $20.0 million. As of September 30~~2025, ~~2023,~~with ~~the~~principal ~~Company~~payments isbeginning in ~~compliance~~March ~~with~~2025. ~~all~~Future ~~covenants~~principal ~~under~~payments ~~the Amended 2020 Loan Agreement~~ and ~~has~~final ~~not~~fee ~~received~~payments ~~any~~will ~~notification~~be ormade ~~indication~~as ~~from~~follows ~~Oxford~~(in ~~of an intent to declare the loan due prior to maturity.~~ thousands):

Concurrently with the February 2022 Amendment, the Company issued 40,000 warrants to Oxford to purchase shares of the Company’s common stock at an exercise price of $45.00. Upon issuance, the warrants were classified as equity and recorded at their fair value of $0.7 million. See Note 4 for further discussion of these warrants.


	AS OF
	MARCH 31, 2024
2025	$	86,956
2026	104,348
2027	26,696
Total future minimum payments	218,000
Less: unamortized debt discount	(9,790)
Total debt	$	208,210

The Company’s obligations under the Amended 2020 Loan Agreement are secured by a first priority security interest of substantially all of the Company’s assets with a positive lien on intellectual property. The Amended 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company’s operations, that may require prepayment of the outstanding term loans. Additionally, following the amendment in June 2021, the Amended 2020 Loan Agreement requires the Company to maintain a minimum cash balance of $20.0 million. As of March 31, 2024, the Company was in compliance with all covenants under the Amended 2020 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity.

Concurrently with the amendment in February 2022, the Company issued 40,000 warrants to Oxford to purchase shares of the Company’s common stock at an exercise price of $45.00. Upon issuance, the warrants were classified as equity and recorded at their fair value of $0.7 million. See Note 4 for further discussion of these warrants.

Interest Expense

Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. During the three months ended ~~September~~March 3031, ~~2023~~2024, interest expense was $8.1 million, $1.2 million of which related to non-cash amortization of the debt discount and accretion of the final payment. During the three months ended ~~September~~March 3031, ~~2022, interest expense was $5.5 million, $1.0 million of which related to non-cash amortization of the debt discount and accretion of the final payment. During the nine months ended September 30,~~ 2023, interest expense was $237.6 million, $31.72 million of which related to non-cash amortization of the debt discount and accretion of the final payment. ~~During the nine months ended September~~

30, 2022, interest expense was $11.1 million, $2.2 million of which related to non-cash amortization of the debt discount and accretion of the final payment.

4. STOCKHOLDERS’ EQUITY

Open Market Sale Agreement

In September 2021, the Company entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which it may, from time to time, sell shares of its common stock having an aggregate offering price of up to $200.0 million through the Sales Agent. Pursuant to the Sales Agreement, the Company will pay the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to 3% of the gross sales price per share sold. During each of the nine months ended September 30, 2023 and September 30, 2022, the Company did not issue any shares under the Sales Agreement.

Securities Purchase Agreement

In August 2023, the Company entered into a Securities Purchase Agreement, as amended, or the Purchase Agreement, with the Purchasers, pursuant to which the Company sold and issued 3,621,314 shares of the Company’s common stock for $19.35 per share and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock in the Private Placement. The purchase price of the pre-funded warrants was $19.3499 per pre-funded warrant, with an exercise price of $0.0001 per share. The Company received gross proceeds of $200.0 million from the Private Placement, before deducting $0.4 million of offering expenses payable by the Company. The pre-funded warrants are equity-classified and carried at the instruments’ fair value upon issuance. The pre-funded warrants are exercisable upon issuance pursuant to certain beneficial ownership limitations as defined in the Purchase Agreement and will expire when exercised in full. As of ~~September 30~~March 31, ~~2023~~2024, all pre-funded warrants ~~are~~were still outstanding.

Warrants Issued in Connection with Amended 2020 Loan Agreement

As of ~~September~~March 3031, ~~2023~~2024, the following equity-classified warrants were outstanding, in addition to the pre-funded warrants discussed above:


Expiration Date	Shares of Common Stock Issuable Upon Exercise of Warrants	Exercise Price per Share
July 15, 2030	7,354	$	17.00
February 18, 2032	40,000	$	45.00

The Company’s warrants are equity-classified and carried at the instruments’ fair value upon classification into equity, with no subsequent remeasurements.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance as of March 31, 2024 and December 31, 2023 consisted of the following (in thousands):

	AS OF	AS OF
	SEPTEMBER 30, 2023	DECEMBER 31, 2022
	MARCH 31, 2024	DECEMBER 31, 2023
Options to purchase common stock issued and outstanding	64,~~668~~623	56,~~305~~494
Shares available for future equity grants	~~437~~2,432	~~162~~533
Pre-funded warrants issued and outstanding	6,715	—6,715
Warrants issued and outstanding	47	47
Total common stock reserved for future issuance	13,~~867~~817	513,~~514~~789

5. EQUITY COMPENSATION PLAN

Stock Incentive Plan

The Company’s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of ~~September~~March 3031, ~~2023~~2024, an aggregate of 79.87 million ~~shares of common stock were authorized for issuance under the 2017 Plan, of which 0.4 million remain available for issuance.~~

shares of common stock were authorized for issuance under the 2017 Plan, of which 2.4 million remained available for issuance.

Stock Option Activity

The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to the fair market value of the Company’s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years.

A summary of the Company’s stock option activity under its 2017 Plan for the three months ended March 31, 2024 is as follows (in thousands, except for per share data and years):

	Number of Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2022	5,305	$	22.95
Outstanding as of December 31, 2023	6,494	$	23.22
Granted	1,575	$	23.00
Exercised	(1,865)	$	21.65
Exercised	(105)	$	11.72
Forfeited	(6)	$	32.97
Forfeited	(107)	$	29.04
Outstanding as of March 31, 2024	4,623	$	23.84	7.6	$	52,413
Outstanding as of September 30, 2023	6,668	$	23.04	7.8	$	12,290
Vested and exercisable as of March 31, 2024	1,892	$	22.84	6.3	$	23,474
Vested and exercisable as of September 30, 2023	3,134	$	21.19	6.8	$	10,480

The aggregate intrinsic value of stock options exercised during the ~~nine~~three months ended ~~September~~March 3031, ~~2023~~2024 and ~~September~~March 3031, ~~2022~~2023 was $125.35 million and $10.4 million, respectively. Aggregate intrinsic value of stock options exercised and outstanding is calculated using the fair value of common stock on the date of exercise and the fair value of common stock as of ~~September~~March 3031, ~~2023~~2024, respectively. The total fair value of stock options vested during the ~~nine~~three months ended ~~September~~March 3031, ~~2023~~2024 and ~~September~~March 3031, ~~2022~~2023 was $198.03 million and $207.7 million, respectively. The Company expects all outstanding stock options to vest.

Stock-Based Compensation Expense

The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value, for the ~~nine~~three months ended ~~September~~March 3031, 2023 ~~and September 30, 2022~~ were as follows:

	NINE MONTHS ENDED SEPTEMBER 30,
				THREE MONTHS ENDEDMARCH 31, 2023
	2023			2022
Risk-free interest rate				3.81		%
Risk-free interest rate	3.76		%	2.45		%
Expected volatility				84.31		%
Expected volatility	84.33		%	85.23		%
Expected dividend yield				—		%
Expected dividend yield	—		%	—		%
Expected term (in years)				6.08
Expected term (in years)	6.08			6.08
Weighted average fair value				$	17.95
Weighted average fair value	$	16.89		$	17.15

19The Company did not grant any stock options during the three months ended March 31, 2024.

Stock-based compensation expense for stock options consisted of the following (in thousands):

	THREE MONTHS ENDEDSEPTEMBER 30,				NINE MONTHS ENDEDSEPTEMBER 30,
	THREE MONTHS ENDEDMARCH 31,
	2023		2022		2023		2022
	2024		2023
Research and development	$	4,~~326~~192	$	3,~~545~~849	$	~~12,420~~	$	~~10,764~~
General and administrative	2,~~204~~205		1,~~146~~787		~~5,999~~		~~4,331~~
Total stock-based compensation expense	$	6,~~530~~397	$	45,~~691~~636	$	~~18,419~~	$	~~15,095~~

As of ~~September~~March 3031, ~~2023~~2024, the Company had $5845.92 million of total unrecognized stock-based compensation expense related to its stock options, which is expected to be recognized over a weighted-average period of 2.63 years.

6. ~~LICENSE AND GRANT REVENUES~~ LEASES

	THREE MONTHS ENDEDSEPTEMBER 30,				NINE MONTHS ENDEDSEPTEMBER 30,
	2023		2022		2023		2022
License fee revenue
Chiesi Farmaceutici S.p.A.	$	119	$	264	$	166	$	603
Phylaxis BioScience, LLC	—		14		—		1,101
2seventy bio, Inc.	—		—		—		200
Total license fee revenue	119		278		166		1,904
Grant revenue	—		—		—		14
Total revenue	$	119	$	278	$	166	$	1,918

License and Collaboration Agreements

Chiesi

In May 2019, the Company entered into an Option Agreement, as amended by the First Amendment to Option Agreement, dated August 19, 2019, or the Chiesi Option Agreement, with Chiesi Farmaceutici S.p.A., or Chiesi, pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. Additionally, the Chiesi Option Agreement provided Chiesi with a right of negotiation for INBRX-101 development and commercialization rights in the United States and Canada in the event that the Company engages in discussions with any third parties for such rights during the term of the Chiesi Option Agreement. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $10.0 million in August 2019.

The Company identified one performance obligation as of the effective date of the Chiesi Option Agreement, which was to perform research and development services for Chiesi during the option period. The Company determined that the option to grant a license in the future was not a material right. The $10.0 million upfront payment was allocated to the single performance obligation. Revenue was recognized over time as services were performed during the option period, based on the Company’s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period.

On July 24, 2023, the Company provided a copy of the European Medicines Agency, or EMA, scientific advice to Chiesi upon receipt, which fulfilled the necessary deliverables to Chiesi and triggered the start of its 60-day option period window. On September 18, 2023, the Company was notified that Chiesi declined to exercise its option.

During the three months ended September 30, 2023 and September 30, 2022, the Company recognized approximately $0.1 million and $0.3 million in revenue related to this agreement, respectively. During the nine months ended September 30, 2023 and September 30, 2022, the Company recognized approximately $0.1 million

and $0.6 million in revenue related to this agreement, respectively. As of September 30, 2023, the Company had no deferred revenue remaining related to this agreement. As of December 31, 2022, the Company had $0.1 million of deferred revenue related to this agreement, all of which was classified as current deferred revenue.

Phylaxis

In July 2020, the Company entered into a joint venture with Phylaxis BioScience, LLC, or Phylaxis. In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement and Master Services Agreement, or collectively, the Phylaxis Agreements, pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. To date, the Company has received $5.0 million in connection with the Phylaxis Agreements. The Company also received a 10% equity interest in Phylaxis as consideration for the contribution of the license of the Company’s intellectual property and know-how and is entitled to receive an additional 5% based on the achievement of certain milestones, in addition to a share in a percentage of the profits of Phylaxis under the Phylaxis Agreements. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $225.0 million and $175.0 million, respectively.

During the three and nine months ended September 30, 2023, the Company recognized no revenue related to this performance obligation following its completion in 2022. During the three months ended September 30, 2022, the Company recognized $14,000 of revenue related to this performance obligation. During the nine months ended September 30, 2022, the Company recognized $1.1 million of revenue related to this performance obligation. As of September 30, 2023 and December 31, 2022, there was no deferred revenue remaining related to the Phylaxis Agreements.

2seventy

In June 2020, the Company entered into an Option and License Agreement with bluebird bio, Inc., or bluebird, pursuant to which the Company granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. In November 2021, bluebird assigned this agreement, or the 2020 2seventy Agreement, to 2seventy bio, Inc., or 2seventy, in connection with bluebird’s internal restructuring and subsequent spin-out of 2seventy.

In June 2020, the Company received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. For each program selected by 2seventy, the Company granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option.

In June 2022, pursuant to the terms regarding the addition of new programs in the 2020 2seventy Agreement, the Company received a $0.2 million upfront option fee related to the selection of a third program and transferred the related know-how and development license. The Company recognized the $0.2 million of revenue at the point in time in which the program was added and the program term began.

During the nine months ended September 30, 2022, the Company recognized $0.2 million of revenue related to this agreement. During the three months ended September 30, 2022, the Company did not recognize any revenue related to this agreement. During the three and nine months ended September 30, 2023, the Company did not recognize any revenue related to this agreement.

7. LEASES

Operating Leases

In September 2017, the Company entered into a seven-year lease agreement as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional five years, which is not included in the right-of-use asset and lease liabilities. The lease contained an initial base rent of approximately $0.1 million per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually.

of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually.

In May 2019, the Company executed an amendment to its lease agreement to expand its facilities and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $30,000 per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually.

The operating right-of-use asset and operating lease liability as of ~~September~~March 3031, ~~2023~~2024 and December 31, ~~2022~~2023 ~~are~~were as follows (in thousands):

	AS OF		AS OF
	SEPTEMBER 30, 2023		DECEMBER 31, 2022
	MARCH 31, 2024		DECEMBER 31, 2023
Operating right-of-use asset	$	32,~~408~~487	$	42,~~717~~952
Operating lease liability
Current	$	2,~~011~~117	$	12,~~860~~063
Non-current	~~1,646~~561		$	31,~~173~~110
Total operating lease liability	$	32,~~657~~678	$	53,~~033~~173

During ~~each of~~ the three months ended ~~September~~March 3031, ~~2023~~2024 and ~~September~~March 3031, ~~2022~~2023, the Company recognized operating lease expense of $0.98 million. ~~During the nine months ended September 30, 2023~~ and ~~September 30, 2022, the Company recognized operating lease expense of~~ $20.69 million ~~and $2.5 million~~, respectively. During each of the three months ended ~~September~~March 3031, ~~2023~~2024 and ~~September~~March 3031, ~~2022~~2023, the Company paid $0.~~5 million in cash for amounts included in the measurement of the operating lease liability. During each of the nine months ended September 30, 2023 and September 30, 2022, the Company paid $1.~~6 million in cash for amounts included in the measurement of the operating lease liability.

As of ~~September~~March 3031, ~~2023~~2024 and December 31, ~~2022~~2023, the Company’s operating lease had a remaining term of 1.83 and 21.5 years, respectively. The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company ~~has~~ determined a weighted-average discount rate of 8.2% as of ~~September~~March 3031, ~~2023~~2024 and December 31, ~~2022~~2023.

Future minimum rental commitments for the Company’s operating leases reconciled to the operating lease liability are as follows (in thousands):

	AS OF
	SEPTEMBER 30, 2023
	MARCH 31, 2024
2023	$	555
2024	1,690
2024	2,247
2025	1,137
Thereafter	—
Total future minimum lease payments	$	32,~~939~~827
Less: imputed interest	(~~282~~149)
Present value of operating lease liability	32,~~657~~678
Less: current portion of operating lease liability	(2,~~011~~117)
Non-current portion of operating lease liability	$	~~1,646~~561

227. COMMITMENTS AND CONTINGENCIES

8. COMMITMENTS AND CONTINGENCIES

Purchase Commitments

The Company has several ongoing contracts with CROs for preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. While these contracts are generally cancellable, some may contain specific activities that involve one or more noncancellable commitments, including minimum purchase commitments, binding annual forecasts and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from cost of work performed to date and up to twelve months of future committed manufacturing costs. As of September 30, 2023 and December 31, 2022, the noncancellable portion of these contracts total in aggregate, excluding amounts paid or incurred at each respective date, approximately $52.5 million and $74.8 million, respectively. The noncancellable purchase commitments relate to the purchase of raw materials and future contract manufacturing of drug supply for INBRX-101. During the nine months ended September 30, 2023 and September 30, 2022, the Company incurred $4.3 million and $0.8 million, respectively, of expenses related to its noncancellable purchase agreements.

Litigation

~~The~~Other than as described below, the Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

23I-Mab Litigation

On March 1, 2022, I-Mab Biopharma, or I-Mab, filed a lawsuit against the Company and Brendan Eckelman, the Company’s co-founder and Chief Scientific Officer, in the United States District Court for the District of Delaware, C.A. No. 22-00276-CJB, asserting claims for misappropriation of trade secrets related to Dr. Eckelman’s service as an expert witness for Tracon Pharmaceuticals, Inc., or Tracon, in Tracon’s arbitration against I-Mab. The parties are currently engaged in expert discovery and summary judgment motions are expected to be filed in or around June 2024, with trial currently scheduled to commence in October 2024. I-Mab is seeking royalty damages and alternative damages in the form of unjust enrichment.

The Company is unable to reasonably estimate possible damages or a range of possible damages in this matter given the uncertainty and therefore has not recorded a liability on its books as of March 31, 2024.

Purchase Commitments

The Company has several ongoing contracts with CROs for preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. While these contracts are generally cancellable, some may contain specific activities that involve one or more noncancellable commitments, including minimum purchase commitments, binding annual forecasts and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from cost of work performed to date and up to twelve months of future committed manufacturing costs. As of March 31, 2024 and December 31, 2023, the noncancellable portion of these contracts totaled in aggregate, excluding amounts paid or incurred at each respective date, approximately $44.8 million and $62.8 million, respectively. The noncancellable purchase commitments relate to the purchase of raw materials and future contract manufacturing of drug supply for INBRX-101.

Contingencies

In connection with the proposed Merger, the Company engaged legal counsel under a contingent fee arrangement. Under this agreement, the Company is obligated to pay a fee of $20.0 million, contingent upon the consummation of the proposed transaction.

The Company also engaged financial advisors under a contingent fee arrangement. Under this agreement, the Company is obligated to pay a fee of 2.0% of the total aggregate consideration paid in the proposed Merger, or $45.0 million.

In the event the Merger is not completed, the Company does not owe any fees to its legal counsel or financial advisors under these agreements. The Company will incur these costs in full upon the consummation of the Merger, if and when it is completed, and has not incurred any portion of these fees as of March 31, 2024.

8. SUBSEQUENT EVENTS

In April 2024, pre-funded warrants to purchase 2,747,245 shares of the Company’s common stock, as issued under the Purchase Agreement, were exercised at an exercise price of $0.0001 per share. Pre-funded warrants to purchase 3,967,391 shares of the Company’s common stock remain outstanding.

From April 1, 2024 through May 7, 2024, a total of 680,001 stock options under the 2017 Plan were exercised at a weighted average exercise price of $15.93. The Company received total proceeds of $10.8 million upon exercise of these stock options.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our condensed consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report, and our audited consolidated financial statements and notes thereto as of and for the fiscal year ended December 31, ~~2022~~2023 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2022~~2023, filed with the SEC on ~~March~~February 628, ~~2023~~2024. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report contain forward-looking statements that involve risk and uncertainties, including those described in the section titled “Special Note Regarding Forward-Looking Statements.” As a result of many factors, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. InWe ~~particular,~~leverage our ~~proprietary~~innovative ~~single~~protein ~~domain~~engineering ~~antibody,~~technologies orand ~~sdAb,~~deep ~~platform~~understanding ~~allows~~of ustarget biology to ~~pursue~~create ~~validated~~therapeutic ~~targets~~candidates with ~~clinical~~attributes ~~promise~~and ~~where~~mechanisms ~~other~~superior ~~antibody~~to ~~and~~current ~~biologic based~~ approaches ~~have failed. Highly modular, our platform technologies can be combined with precise valencies~~ and ~~multiple~~applicable ~~specificities, creating therapeutic candidates designed~~ to bea ~~capable~~range of ~~enhanced cell signaling~~challenging, ~~conditional~~validated ~~activation~~targets orwith ~~combined~~high ~~synergistic functions~~potential.

WeSale ~~have multiple programs in various stages~~ of ~~development~~INBRX-101 ~~from discovery~~ to preclinical to clinical. We currently have four programs in ongoing clinical trials. Three of these programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency, or AATD, as shown below:Sanofi

INBRX-101

INBRX-109

INBRX-105

INBRX-106

AAT-Fc fusion protein

Tetravalent DR5 agonist

PD-L1x4-1BB tetravalent conditional agonist

Hexavalent OX40 agonist

In January 2024, we announced that we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Aventis, a wholly owned indirect subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency, or AATD. Immediately prior to the closing of the proposed merger, or the Merger, all assets and liabilities not primarily related to INBRX-101 will be spun out into a new publicly traded company, New Inhibrx.

24Under the terms of the Merger Agreement, Aventis will acquire all of our outstanding shares through the Merger, and in turn, each of our shareholders will receive: (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone and (iii) one SEC-registered, publicly listed, share of New Inhibrx for every four shares of Inhibrx common stock held. In addition, in connection with the transaction, Aventis will (1) assume and retire our outstanding third-party debt, including our debt arrangements with Oxford Finance LLC, or Oxford, (2) cause New Inhibrx to be funded with $200 million in cash, and (3) retain an equity interest in New Inhibrx of approximately 8%. Subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals, we expect the Merger to close during the second quarter of 2024.

Program

Therapeutic Area

Target(s)/Format

STAGE OF DEVELOPMENT

Preclinical

Phase 1

Phase 2

Phase 3

INBRX-101

Orphan/Respiratory

Neutrophil ElastaseAAT-Fusion Protein

INBRX-109*

Oncology

DR5Tetravalent Agonist

INBRX-105**

Oncology

PD-L1 x 4-1BB Tetravalent Conditional Agonist

INBRX-106**

Oncology

OX40Hexavalent Agonist

Current Clinical Pipeline

Our current clinical pipeline includes therapeutic candidates in the following categories:

INBRX-101

INBRX-109

INBRX-106

AAT-Fc fusion
protein

Tetravalent DR5
agonist

Hexavalent OX40
agonist

Program

Therapeutic Area

Target(s)/Format

STAGE OF DEVELOPMENT

Preclinical

Phase 1

Phase 2

Phase 3

INBRX-101*

Orphan/Respiratory

Neutrophil Elastase
AAT-Fusion Protein

INBRX-109**

Oncology

DR5
Tetravalent Agonist

INBRX-106***

Oncology

OX40
Hexavalent Agonist

__________________

* ~~Third~~Subject ~~party~~to ~~partnership~~potential ~~with~~acquisition ~~Chinese~~by ~~biotechnology~~Aventis ~~company,~~as ~~Transcenta~~described ~~Holding, Ltd~~above.~~, or Transcenta, currently in place for development and commercialization in China, Hong Kong, Macau and/or Taiwan.~~

** ~~Third~~ Currently ~~party~~being ~~partnership~~investigated ~~with Chinese biotechnology company, Elpiscience Biopharmaceuticals, Inc., or Elpiscience, currently~~ in ~~place~~colorectal ~~for development~~ and ~~commercialization~~gastric ~~in China~~adenocarcinomas, ~~Hong~~malignant ~~Kong~~pleural mesothelioma, ~~Macau~~chondrosarcoma and~~/or~~ ~~Taiwan.~~synovial sarcoma.

~~INBRX-101~~*** Currently isbeing aninvestigated optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy candidate for AATD. In March 2022, the United States Food and Drug Administration, or FDA, granted orphan drug designation for INBRX-101 for the treatment of AATD. In May 2022, we announced topline results from the INBRX-101 Phase 1 clinical trial. We believe the data revealed the potential to achieve normal AAT levels with less frequent dosing than the current standard of care and showed the treatment was well tolerated with no drug-related severe or serious adverse events at doses up to and including 120 mg/kg in ~~single and multi-dose administered intravenously. In April 2023, we initiated ElevAATe, a registration-enabling trial for INBRX-101 for the treatment of~~ patients with ~~emphysema~~non-small ~~due~~cell tolung ~~AATD. The primary endpoint of the trial is the mean change in the average functional AAT~~cancer, or ~~fAAT~~NSCLC, concentration as measured by anti-neutrophil elastase capacity from baseline to average serum trough fAAT concentration at steady state (Ctrough,ss). The initial read-out from the ElevAATe trial is expected to occur in late 2024 and wehead ~~intend to submit for regulatory approval once completed. In our end of Phase 1 meeting, the FDA requested additional information to support the correlation between serum AAT levels~~ and ~~the~~neck ~~clinical~~squamous ~~benefit~~cell ~~in AATD to further support serum AAT levels as a surrogate endpoint reasonably likely to predict clinical benefit. We are in the process of compiling this data through existing registry~~carcinoma, ~~health~~or ~~records and published data and plan to submit those analyses to the FDA as part of the BLA submission~~HNSCC. ~~In May 2023, the FDA granted Fast Track designation to INBRX-101 for the treatment of patients with emphysema due to AATD.~~

~~Our most advanced therapeutic candidate,~~ INBRX-109, is a tetravalent death receptor 5, or DR5, agonist currently being evaluated in patients diagnosed with difficult-to-treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, Ewing sarcoma and pancreatic adenocarcinoma. In June 2021, based on the initial Phase 1 data results, we initiated a registration-enabling Phase 2 trial for the treatment of unresectable or metastatic conventional chondrosarcoma for which the FDA and the European Medicine Agency, or EMA, granted orphan drug designation in November 2021 and August 2022, respectively. In November 2022, we announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for the treatment of chondrosarcoma, which showed disease control was observed in patients with and without isocitrate dehydrogenase, or IDH, mutations. Data from the registration-enabling trial in unresectable or metastatic conventional chondrosarcoma is expected during the second half of 2024. 101

OnINBRX-101 ~~November~~is 2,an ~~2023~~optimized, werecombinant ~~announced~~alpha-1 ~~preliminary~~antitrypsin, ~~efficacy~~or ~~and~~AAT, ~~safety~~augmentation ~~data~~therapy ~~from~~candidate ~~the~~for ~~Phase~~AATD. 1In ~~trial~~March of2022, ~~INBRX-109~~the inUnited ~~combination~~States ~~with~~Food ~~Irinotecan~~and Drug Administration, or ~~IRI~~FDA, ~~and~~granted ~~Temozolomide,~~orphan ordrug ~~TMZ,~~designation for INBRX-101 for the treatment of ~~advanced~~AATD. orIn ~~metastatic~~May 2022, ~~unresectable~~we ~~Ewing~~announced ~~sarcoma.~~topline ~~Among~~results from the 13INBRX-101 ~~patients~~Phase ~~evaluable~~1 asclinical oftrial. We believe the data ~~cut~~revealed ofthe ~~September~~potential 8,to ~~2023,~~achieve ~~the~~normal ~~observed~~AAT ~~disease~~levels ~~control~~with ~~rate~~less ~~was~~frequent ~~76.9%,~~dosing orthan 10the ~~out~~current standard of 13care ~~patients~~and asshowed ~~measured~~the bytreatment ~~RECISTv1.1,~~was well tolerated with 7no ~~patients~~drug-related ~~achieving~~severe ~~partial~~or ~~responses~~serious ~~(53.8%)~~AEs at doses up to and 3including ~~patients~~120 ~~achieving~~mg/kg ~~stable~~in ~~disease~~single ~~(23~~and multi-dose administered intravenously.~~1%).~~ ~~Overall~~In May 2023, the FDA granted Fast Track designation to INBRX-~~109~~101 infor ~~combination~~the ~~with~~treatment ~~IRI/TMZ~~of ~~was~~patients ~~well~~with ~~tolerated~~emphysema ~~from~~due ato ~~safety perspective~~AATD.

25In April 2023, we initiated ElevAATe, a registration-enabling trial for INBRX-101 for the treatment of patients with emphysema due to AATD. The primary endpoint of the trial is the mean change in the average functional AAT, or fAAT, concentration as measured by anti-neutrophil elastase capacity from baseline to average serum trough fAAT concentration at steady state (Ctrough,ss). The initial read-out from the ElevAATe trial is expected to occur in

INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1, which is typically found in the tumor microenvironment and associated lymphoid tissues. It is currently being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. Parts 1 and 3, dose escalation as a single agent and in combination with Keytruda, have been completed. We continue to enroll and/or have active patients in Part 2, single agent dose expansion, and Part 4, combination expansion cohorts. We expect to announce initial data from these cohorts mid-year of 2024. 22

~~INBRX~~mid-~~106~~2025 isand awe ~~precisely~~intend ~~engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed~~ to besubmit anfor ~~optimized~~regulatory ~~agonist~~approval ofonce ~~this co-stimulatory receptor~~completed. ItIn isour ~~currently~~end ~~being~~of ~~investigated~~Phase as1 ameeting, ~~single~~the ~~agent~~FDA ~~and~~requested inadditional ~~combination~~information ~~with~~to ~~Keytruda~~support inthe ~~patients~~correlation ~~with~~between ~~locally~~serum ~~advanced~~AAT orlevels ~~metastatic solid tumors. Parts 1~~ and 3,the ~~dose~~clinical ~~escalation~~benefit ~~as a single agent and~~ in ~~combination~~AATD ~~with Keytruda, have been completed. It was observed~~ to befurther ~~well~~support ~~tolerated,~~serum ~~with~~AAT ~~predominantly~~levels ~~mild~~as ora ~~moderate~~surrogate ~~immune-related~~endpoint ~~toxicities~~reasonably ~~notes.~~likely Weto ~~observed~~predict ~~durable~~clinical ~~responses across multiple tumor types~~benefit. We ~~continue~~are ~~to enroll and/or have active patients~~ in ~~Part~~the 2,process ~~single~~of ~~agent~~compiling ~~dose~~this ~~expansion,~~data ~~and~~through ~~Part~~existing 4registry, ~~combination~~health ~~expansion~~records ~~cohorts.~~and Wepublished ~~expect~~data tofor ~~announce~~the ~~initial~~FDA ~~data~~as ~~from~~part ~~these~~of ~~cohorts during~~ the ~~second~~BLA ~~half of 2024~~submission.

As described above, we expect our INBRX-101 program to be acquired by Sanofi during the second quarter of 2024.

INBRX-109

Our most advanced therapeutic candidate, INBRX-109, is a tetravalent death receptor 5, or DR5, agonist currently being evaluated in patients diagnosed with difficult-to-treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, Ewing sarcoma and pancreatic adenocarcinoma. In June 2021, based on the initial Phase 1 data results, we initiated a registration-enabling Phase 2 trial for the treatment of unresectable or metastatic conventional chondrosarcoma for which the FDA and the European Medicine Agency, or EMA, granted orphan drug designation in November 2021 and August 2022, respectively. In November 2022, we announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for the treatment of chondrosarcoma, which showed disease control was observed in patients with and without isocitrate dehydrogenase, or IDH, mutations. Of the 210 patients studied to date, the treatment-related serious adverse events observed were (i) abnormal laboratory findings of increased alanine aminotransferase (6 or 2.9%), increased aspartate aminotransferase (6 or 2.9%), increased hepatic enzyme (1 or 0.5%), increased liver function test (1 or 0.5%) and decreased platelet count (1 or 0.5%), (ii) gastrointestinal disorders, which consisted of diarrhea (3 or 1.4%), enterocolitis, an inflammation of the small intestine and colon (1 or 0.5%), nausea (1 or 0.5%) and vomiting (1 or 0.5%), (iii) blood and lymphatic system disorders, which consisted of anemia (3 or 1.4%), febrile neutropenia, a condition where the body has a reduced number of a certain type of white blood cells in conjunction with a fever (2 or 1%) and thrombocytopenia, a condition where the number of platelets in the blood is abnormally low (1 or 0.5%), (iv) hepatobiliary (liver, bile duct or gallbladder) disorders which consisted of acute hepatic failure (2 or 1%), hepatic failure (1 or 0.5%), hyperbilirubinemia, also known as jaundice (1 or 0.5%), (v) general disorders and administration site conditions, which consisted of asthenia, or physical weakness or general lack of energy (1 or 0.5%) and influenza-like illness (1 or 0.5%), (vi) infections, which consisted of neutropenic sepsis, a significant inflammatory response to a presumed infection in a person with or without fever (1 or 0.5%) and sepsis, an overreactive and extreme inflammatory response to infection (1 or 0.5%), (vii) metabolism and nutrition disorders, which consisted of dehydration (1 or 0.5%), failure to thrive (1 or 0.5%) and hyponatraemia, a condition where the sodium levels in blood are lower than normal (1 or 0.5%), (viii) tachycardia (1 or 0.5%), and (ix) posterior reversible encephalophathy syndrome, a condition marked by headaches, vision problems, mental changes, seizures, and swelling in the brain (1 or 0.5%). Data from the registration-enabling Phase 2 trial in unresectable or metastatic conventional chondrosarcoma is expected during the first half of 2025.

On November 2, 2023, we announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan, or IRI, and Temozolomide, or TMZ, for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Among the 13 patients evaluable as of the data cut of September 8, 2023, the observed disease control rate was 76.9%, or 10 out of 13 patients as measured by RECISTv1.1, with 7 patients achieving partial responses (53.8%) and 3 patients achieving stable disease (23.1%). Overall, INBRX-109 in combination with IRI/TMZ was well tolerated from a safety perspective. Of 89 patients studied to date, the serious adverse events related to study drug (INBRX 109 or placebo) were (i) abnormal laboratory findings of increased alanine aminotransferase (1 or 1.1%) and increased aspartate aminotransferase (1 or 1.1%), (ii) hepatobiliary disorders, which consisted of hyperbilirubinemia (1 or 1.1%) and hepatic failure (1 or 1.1%), which led to our partial clinical hold, as described above, (iii) infections which consisted of infectious enterocolitis (1 or 1.1%), (iv) muscular weakness (1 or 1.1%), and (v) renal and urinary disorders, which consisted of hemorrhagic Cystitis, a condition in which the bladder becomes inflamed and starts to bleed (1 or 1.1%). We have expanded recruitment of this cohort as a result of these preliminary findings.

INBRX-106

INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor. It is currently being investigated as a single agent and in

combination with Keytruda in patients with locally advanced or metastatic solid tumors. Parts 1 and 3, dose escalation as a single agent and in combination with Keytruda, have been completed. We observed durable responses across multiple tumor types. To date, of the 166 patients studied in our Phase 1/2 clinical trial for INBRX-106, the treatment-related serious adverse events observed were (i) general disorders and administration site conditions, which consisted of pyrexia, or fever (3 or 1.8%) and influenza-like illness (1 or 0.6%), (ii) metabolism and nutrition disorders, which consisted of failure to thrive (1 or 0.6%), hyponatraemia, a condition when the sodium levels in blood are lower than normal (1 or 0.6%), and hypercalcemia, a condition when the sodium levels in blood are higher than normal (1 or 0.6%), (iii) gastrointestinal disorders, which consisted of diarrhea (2 or 1.2%) and vomiting (1 or 0.6%), (iv) blood and lymphatic system disorders, which consisted of anemia (1 or 0.6%) and pancytopenia, a condition in which there is lower-than-normal number of red and white blood cells and platelets in the blood (1 or 0.6%), (v) cardiac disorders, which consisted of acute myocardial infarction (1 or 0.6%) and myocarditis (1 or 0.6%), (vi) cytokine release syndrome (2 or 1.2%), (vii) infusion-related reactions (2 or 1.2%), (viii) primary adrenal insufficiency (1 or 0.6%), (ix) increased blood bilirubin (1 or 0.6%), (x) myositis, or inflamed muscles (1 or 0.6%), (xi) toxic encephalopathy, or brain dysfunction caused by toxic exposure (1 or 0.6%), and (xii) acute kidney injury (1 or 0.6%). Notably, though, most patients with related treatment emergent adverse events had events that were mild or moderate (Grade 1 or 2) in severity. The most common adverse events observed in this study related to INBRX-106 were infusion-related reaction, fatigue, rash, nausea, pruritus, and diarrhea. We expanded the enrollment for Part 2, single agent dose expansion, to increase the dataset in the single agent cohorts and to enroll additional NSCLC patients. We expect to announce additional data from Part 2 in 2025. We continue to enroll patients with NSCLC and HNSCC in Part 4, combination expansion cohorts. We are in the process of expanding these cohorts and expect to initiate at least one additional cohort by mid 2024. We expect to have a more mature dataset during the third quarter of 2025 and plan to provide an update at that time.

Components of Results of Operations

Revenue

To date, all of our revenue has been derived from licenses with collaboration partners and grant awards. We have not generated any revenue from the commercial sale of approved therapeutic products, ~~and~~to until, if ever, they are approved for commercial sale, we expect our revenue will be derived primarily from payments under our current license agreements and any potential future collaborations or strategic transactionsdate.

Operating Expenses

Research and Development

To date, our research and development expenses have related primarily to research activities, including our discovery efforts, and preclinical and clinical development and the manufacturing of our therapeutic candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We do not track our internal research and development expenses on a program-by-program basis as they primarily relate to personnel, early research and consumable costs, which are deployed across multiple projects under development.

~~Research~~In accordance with the applicable accounting and regulatory requirements, we track all research and development expenses in the aggregate and do not manage or track either external or internal expenses on a program-by-program basis. External research and development expenses are instead managed and tracked by the nature of the activity, and primarily consist of contract manufacturing and clinical trial expenses. Internal research and development expenses primarily relate to personnel, early research and consumable costs, which are deployed across multiple projects under development. We manage and prioritize our research and development expenses based on scientific data, probability of: successful technical development and regulatory approval, market potential and unmet medical need, among other considerations. We regularly review our research and development activities and, as necessary, reallocate resources that we believe will best support the long-term growth of our overall business. We review expenses incurred by vendor and by contract as benchmarked against the progression of our clinical and other milestones.

•External research and development expenses, ~~consisting~~consist of:

◦•expenses incurred in connection with the preclinical development of our programs;

◦•clinical trials of our therapeutic candidates, including under agreements with third parties, such as consultants and contract research organizations, or CROs;

◦•expenses associated with the manufacturing of our therapeutic candidates under agreements with contract development and manufacturing organizations, or CDMOs;

~~◦expenses associated with regulatory requirements, including fees and other expenses related to our Scientific Advisory Board; and~~24

~~◦other~~•expenses ~~external~~associated ~~expenses~~with regulatory requirements, ~~such~~including asfees ~~laboratory~~and ~~services~~other expenses related to our ~~discovery~~Scientific ~~and~~Advisory ~~development~~Board; ~~programs~~ and ~~other shared services, and~~

•~~Internal~~other external expenses, ~~consisting~~such ~~of:~~as laboratory services related to our discovery and development programs and other shared services.

~~◦salaries,~~Internal ~~benefits and other related costs, including non-cash stock-based compensation, for personnel engaged in~~ research and development ~~functions;~~expenses consist of:

~~◦facilities~~•salaries, ~~depreciation~~benefits and other ~~expenses~~related costs, ~~which~~including ~~include~~non-cash ~~direct~~stock-based ~~and~~compensation, ~~allocated expenses~~ for ~~depreciation~~personnel ~~and~~engaged ~~amortization,~~in ~~rent~~research and ~~maintenance~~development ~~of facilities~~functions; ~~and~~

~~◦other~~•facilities, ~~internal~~depreciation and other expenses, ~~such~~which asinclude ~~laboratory~~direct ~~supplies~~ and ~~other~~allocated ~~shared~~expenses ~~research~~for depreciation and ~~development~~amortization, ~~costs.~~rent and maintenance of facilities; and

26•other internal expenses, such as laboratory supplies and other shared research and development costs.

We expect that research and development expense will continue to increase over the next several years as we continue development of our therapeutic candidates currently in clinical stage development, support our preclinical programs, and continue to discover new therapeutic candidates, as well as increase our headcount. In particular, clinical development of our therapeutic candidates, as opposed to preclinical development, generally has higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Moreover, the costs associated with our CDMOs to manufacture our therapeutic candidates and future commercial products is also much more costly as compared to early stage preclinical development. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our therapeutic candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical and clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which therapeutic candidates to pursue and how much funding to direct to each therapeutic candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each therapeutic candidate’s commercial potential. We will need substantial additional capital in the future to support these efforts. In addition, we cannot forecast which therapeutic candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

Our clinical development costs may vary significantly based on factors such as:

•the per patient trial costs;

•the number of trials required for approval;

•the number of sites included in the trials;

•the countries in which the trials are conducted;

•the length of time required to enroll eligible patients;

•the number of patients that participate in the trials;

•the number of doses that patients receive;

•the drop-out or discontinuation rates of patients;

•the potential additional safety monitoring requested by regulatory agencies;

•the duration of patient participation in the trials and follow-up;

•the cost, timing, and successful manufacturing of our therapeutic candidates;

•the phase and development of our therapeutic candidates;

•the efficacy and safety profile of our therapeutic candidates; and

•the uncertainties related to potential economic downturn, geopolitical events and widespread health events on capital and financial markets.

General and Administrative

General and administrative, or G&A, expenses consist primarily of:

•salaries, benefits and other related costs, including non-cash stock-based compensation, for personnel engaged in G&A functions;

•expenses incurred in connection with accounting and audit services, legal services, including costs associated with obtaining and maintaining our patent portfolio, investor relations and consulting expenses under agreements with third parties, such as consultants and contractors;

•expenses incurred in connection with commercialization and business development activity; and

•facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities, insurance and supplies.

We expect our G&A expenses will continue to increase in the future to support our continued research and development activities. We expect increased costs related to pre-commercialization and business development activities, including the hiring of additional personnel as we continue to build our commercial team in preparation for our future product launches. Additionally, we expect other professional service fees to increase, including but not limited to, patent-related costs for filing, prosecution and maintenance of our product candidates, and compliance costs, accounting, legal, investor and public relations and additional personnel.

Other Income (Expense)

Interest expense. Interest expense consists of interest on our loans with Oxford ~~Finance LLC, or Oxford~~.

Interest income. Interest income consists of interest earned on cash and cash equivalents, which include investments held during the period in highly liquid debt securities with original maturities of less than three months from our date of acquisition.

2826

Results of Operations

Comparison of the Three Months Ended ~~September~~March 3031, ~~2023~~2024 and ~~September~~March 3031, ~~2022~~2023

The following table summarizes our condensed consolidated results of operations for each of the periods indicated (in thousands, except percentages):

	THREE MONTHS ENDEDSEPTEMBER 30,				CHANGE
	THREE MONTHS ENDEDMARCH 31,				CHANGE
	2023		2022		($)		(%)
	2024		2023		($)		(%)
Revenue:
License fee revenue	$	~~119~~—	$	~~278~~17	$	(~~159~~17)	(57100)	%
Total revenue	~~119~~—		~~278~~17		(~~159~~17)		(57100)	%
Operating expense:
Research and development	3863,~~057~~851		2437,~~934~~386		1326,~~123~~465		5371	%
General and administrative	79,~~889~~974		56,~~347~~397		23,~~542~~577		4856	%
Total operating expense	4573,~~946~~825		3043,~~281~~783		1530,~~665~~042		5269	%
Loss from operations	(4573,~~827~~825)		(3043,~~003~~766)		(1530,~~824~~059)		5369	%
Other income (expense)
Interest expense	(8,~~149~~130)		(57,~~547~~563)		(~~2,602~~567)		477	%
Interest income	23,~~324~~304		~~207~~2,483		~~2,117~~821		~~1,023~~33	%
Other income (expense), net	(135)		18		(153)		(850)	%
Other expense, net	(59)		(70)		11		(16)	%
Total other expense	(54,~~960~~885)		(5,~~322~~150)		~~(638)~~265		12(5)	%
Provision for income taxes	2		—		2		100	%
Net loss	$	(78,710)	$	(48,916)	$	(29,794)	61	%
Net loss	$	(51,789)	$	(35,325)	$	(16,464)	47	%

License Fee Revenue

License fee revenue ~~decreased by $0.2 million from $0.3 million~~ during the three months ended ~~September~~March 3031, ~~2022~~2023 towas $~~0.1 million during the three months ended September 30~~17,000 ~~2023. During the three months ended September 30, 2023~~ and ~~September 30,~~consisted ~~2022, we recognized $0.1 million and $0.3 million, respectively,~~ of ~~license fee~~ revenue related to our option agreement, or the Chiesi Option Agreement, with Chiesi Farmaceutici S.p.A., or Chiesi. ~~Upon~~We ~~Chiesi’s~~did ~~declination~~not ofrecognize ~~its~~any ~~option, all remaining deferred~~ revenue ~~under this agreement was recognized~~ during the ~~period. Additionally, during the~~ three months ended ~~September~~March 3031, ~~2022,~~2024 wefollowing ~~recognized~~our ~~all~~recognition ~~remaining~~of ~~deferred~~all revenue ~~related~~under tothe ~~our~~Chiesi ~~agreements~~Option ~~with~~Agreement ~~Phylaxis BioScience, LLC, or Phylaxis, for total license fee revenue of approximately $14,000~~ during the ~~period.~~prior year.

Research and Development Expense

The following table sets forth the primary external and internal research and development expenses (in thousands, except percentages):

	THREE MONTHS ENDEDSEPTEMBER 30,				CHANGE
	THREE MONTHS ENDEDMARCH 31,				CHANGE
	2023		2022		($)		(%)
	2024		2023		($)		(%)
External expenses:
Contract manufacturing	$	1025,~~475~~202	$	510,~~064~~328	$	514,~~411~~874	~~107~~144	%
Clinical trials	819,~~906~~778		610,~~870~~019		29,~~036~~759		3097	%
Other external research and development	2,~~695~~034		12,~~034~~286		~~1,661~~(252)		~~161~~(11)	%
Internal expenses:
Personnel	1213,~~498~~238		911,~~052~~302		31,~~446~~936		3817	%
Equipment, depreciation, and facility	1,~~760~~920		1,~~552~~798		~~208~~122		137	%
Other internal research and development	1,~~723~~679		1,~~362~~653		~~361~~26		272	%
Total research and development expenses	$	3863,~~057~~851	$	2437,~~934~~386	$	1326,~~123~~465	5371	%

Research and development expenses increased by $13.2 million from $24.9 million during the three months ended September 30, 2022 to $38.1 million during the three months ended September 30, 2023. The overall increase was primarily due to the following factors:27

~~•contract~~Research ~~manufacturing~~and ~~expense~~development expenses increased by $526.45 million, ~~due~~from to$37.4 ~~the~~million ~~nature of the development and manufacturing activities performed~~ during the ~~current~~three ~~period~~months atended ~~our~~March ~~CDMO~~31, ~~and~~2023 ~~CRO~~to ~~partners~~$63.9 ~~supporting~~million ~~our~~during ~~clinical and preclinical therapeutic candidates, which reflect~~ the ~~stage-specific~~three ~~needs~~months ofended ~~our~~March ~~programs and include early and late stage drug substance clinical manufacturing~~31, ~~analytical~~2024. ~~development,~~The ~~quality~~overall ~~control,~~increase orwas ~~QC,~~primarily ~~testing~~due ~~and~~to ~~stability~~the ~~studies,~~following ~~as well as drug product development, scale-up, robustness studies and selected biologics license applications, or BLA,-enabling activities;~~factors:

•~~clinical~~contract ~~trial~~manufacturing expense increased by $214.09 million, due to ~~costs~~the ~~incurred~~nature inof the ~~registration-enabling~~development ~~Phase~~and 2manufacturing ~~trial~~activities ~~for~~performed ~~INBRX-101~~during ~~for~~ the ~~treatment~~current ofperiod ~~emphysema~~with ~~due~~our toCDMO ~~AATD~~and ~~which~~CRO wepartners ~~initiated~~supporting ~~during~~our ~~the~~clinical ~~current~~and ~~year,~~preclinical astherapeutic ~~well~~candidates, aswhich reflect the ~~progression~~stage-specific needs of our ~~INBRX-109~~programs ~~registration-enabling~~and ~~Phase~~include 2early ~~trial~~and ~~for~~late ~~the~~stage ~~treatment~~drug ofsubstance ~~unresectable~~clinical ormanufacturing, ~~metastatic~~analytical ~~conventional~~development, ~~chondrosarcoma.~~quality ~~Costs~~control, ~~associated~~or ~~with~~QC, ~~our~~testing ~~Phase~~and ~~1/2~~stability ~~clinical~~studies, ~~trials~~as ~~for~~well ~~INBRX~~as drug product development, scale-~~105~~up, robustness studies and ~~INBRX-106~~selected ~~remained~~biologics ~~consistent~~license inapplications, ~~each~~or ~~period~~BLA,-enabling activities;

•~~personnel-related~~clinical trial expense increased by $39.48 million, ~~which was~~ primarily ~~related~~due to anthe ~~increase~~initiation inof ~~headcount~~our asregistration-enabling aPhase ~~result~~2 oftrial afor ~~significant~~INBRX-101 ~~expansion~~for the treatment of ~~our~~emphysema ~~clinical~~due ~~team~~to AATD during the second quarter of 2023, as well as the ~~issuance~~progression of ~~additional~~our ~~stock~~INBRX-106 ~~options~~Phase 1/2 trial and ~~the~~our ~~expansion~~registration-enabling ofPhase 2 trial for the ~~bonus~~treatment ~~eligibility~~of ~~pool~~unresectable ~~during~~or ~~the~~metastatic ~~current~~conventional ~~year~~chondrosarcoma; and

•~~facility and equipment~~personnel-related expense increased by $01.29 million, which was primarily ~~attributable~~related to an increase in ~~software~~headcount ~~subscriptions~~as toa ~~support~~result ~~research~~of ~~and~~the ~~development~~expansion ~~activities;~~of our technical operations and clinical teams.

•other research and development expense increased by $2.0 million, which was primarily attributable to an increase in clinical-related consulting expenses, the purchase of lab supplies, and preclinical studies.

G&A Expense

G&A expenses increased by $23.6 million from $56.34 million during the three months ended ~~September~~March 3031, ~~2022~~2023 to $710.90 million during the three months ended ~~September~~March 3031, ~~2023~~2024. The overall increase during the three months ended ~~September~~March 3031, ~~2023~~2024 was primarily due to the following factors:

•personnel-related expenses increased by $1.81 million, primarily attributable to an increase in headcount as wein ~~continue~~our tofinance ~~build~~and ~~out~~accounting team and our commercial strategy and medical affairs team~~, as well as increased expense related to additional stock option grants to employees and the expansion of the bonus eligibility pool in the current year~~;

30•professional services-related expenses related to legal and accounting services increased by $1.6 million, which was primarily attributable to increases in legal expenses, including those related to intellectual property and other general corporate matters, in addition to increases in accounting services performed during the period as a result of our filing status in the current year; and

•~~pre-commercialization~~ expenses ~~increased~~related byto the Merger of $0.36 million, ~~primarily~~consisting ~~related~~of toSEC ~~increases~~filing infees and consulting services toperformed ~~support~~in ~~our~~connection ~~commercial~~with ~~operations~~filings ~~business intelligence strategies and our market research expenses~~ related to ~~INBRX-101~~the ~~and~~transaction. ~~INBRX-109; and~~

•professional services-related expense increased by $0.4 million, which was primarily attributable to increases in legal expenses, including those related to intellectual property and other general corporate matters, in addition to increases in accounting services performed during the period as a result of our filing status in the current year.

Other income (expense)

Interest expense. Interest expense increased by $20.65 million from $57.56 million during the three months ended ~~September~~March 3031, ~~2022~~2023 to $8.1 million during the three months ended ~~September~~March 3031, ~~2023~~2024, all of which relates to interest incurred and the amortization of debt discounts related to the ~~Amended~~ 2020 Loan Agreement. ~~The~~with ~~increase~~Oxford inand ~~interest~~subsequent ~~expense~~amendments isbetween ~~the~~November ~~result~~2020 ofand anOctober ~~increase~~2022, inor collectively, the ~~outstanding~~Amended ~~principal~~2020 ~~balance~~Loan ~~from $170~~Agreement.0 ~~million~~The asincrease ofin ~~September 30,~~interest ~~2022~~expense tois ~~$200.0~~the ~~million~~result as of ~~September 30, 2023, as well as~~ an increase in our variable interest rate driven by overall market conditions during the three months ended ~~September~~March 3031, ~~2023~~2024. For more information regarding the Amended 2020 Loan Agreement, refer to Note 3 to the condensed consolidated financial statements.

Interest income. During the three months ended ~~September~~March 3031, ~~2023~~2024, we earned $23.3 million of interest income, ~~of which $1.7 million~~ related to interest earned on our sweep and money market account balances. ~~and~~During the three months ended March 31, 2023, we earned $02.65 million ~~related~~of tointerest ~~the~~income, ~~accretion~~which consisted of ~~discounts~~$1.0 onmillion ~~investments~~of ininterest ~~debt~~income ~~securities~~related ~~during~~to ~~the~~interest ~~period.~~earned ~~During~~on ~~the~~our ~~three~~sweep ~~months~~and ~~ended~~money ~~September~~market ~~30,~~account ~~2022,~~balances weand ~~earned~~ $01.25 million of interest ~~income~~earned on our investments in U.S. Treasury Bills. The increase in interest income during the three months ended ~~September~~March 3031, ~~2023~~2024 is the result of higher cash and cash equivalent balances, coupled with rising interest rates, generating higher returns.

Comparison of the Nine Months Ended September 30, 2023 and September 30, 2022

The following table summarizes our condensed consolidated results of operations for each of the periods indicated (in thousands, except percentages):

	NINE MONTHS ENDEDSEPTEMBER 30,				CHANGE
	2023		2022		($)		(%)
Revenue:
License fee revenue	$	166	$	1,904	$	(1,738)	(91)	%
Grant revenue	—		14		(14)		(100)	%
Total revenue	166		1,918		(1,752)		(91)	%
Operating expense:
Research and development	109,549		79,735		29,814		37	%
General and administrative	21,549		15,800		5,749		36	%
Total operating expense	131,098		95,535		35,563		37	%
Loss from operations	(130,932)		(93,617)		(37,315)		40	%
Other income (expense)
Interest expense	(23,617)		(11,067)		(12,550)		113	%
Interest income	7,221		305		6,916		2268	%
Other income, net	(422)		72		(494)		(686)	%
Total other expense	(16,818)		(10,690)		(6,128)		57	%
Provision for income taxes	7		4		3		75	%
Net loss	$	(147,757)	$	(104,311)	$	(43,446)	42	%

License Fee Revenue

License fee revenue decreased by $1.7 million from $1.9 million during the nine months ended September 30, 2022 to $0.2 million during the nine months ended September 30, 2023. During the nine months ended September 30, 2023 and September 30, 2022, we recognized $0.2 million and $0.6 million, respectively, of license fee revenue related to the Chiesi Option Agreement. Upon Chiesi’s declination of its option, all remaining deferred revenue under this agreement was recognized during the period. Additionally, during the nine months ended September 30, 2022 we recognized license fee revenue of approximately $1.1 million related to our agreements with Phylaxis. Work on the first phase of these agreements was completed and all deferred revenue was recognized during 2022. Accordingly, no revenue was recognized under our agreements with Phylaxis during the nine months ended September 30, 2023. We also recognized $0.2 million of revenue under the 2020 2seventy Agreement following the grant of an exclusive option and development license upon initiation of a third program during the nine months ended September 30, 2022. No revenue was recognized under this agreement with 2seventy during the nine months ended September 30, 2023.

Research and Development Expense

The following table sets forth the primary external and internal research and development expenses (in thousands, except percentages):

	NINE MONTHS ENDEDSEPTEMBER 30,				CHANGE
	2023		2022		($)		(%)
External expenses:
Clinical trials	$	30,473	$	21,380	$	9,093	43	%
Contract manufacturing	25,821		19,016		6,805		36	%
Other external research and development	6,996		4,855		2,141		44	%
Internal expenses:
Personnel	35,895		26,302		9,593		36	%
Equipment, depreciation, and facility	5,294		4,455		839		19	%
Other internal research and development	5,070		3,727		1,343		36	%
Total research and development expenses	$	109,549	$	79,735	$	29,814	37	%

Research and development expenses increased by $29.8 million from $79.7 million during the nine months ended September 30, 2022 to $109.5 million during the nine months ended September 30, 2023. The overall increase was primarily due to the following factors:

•clinical trial expense increased by $9.1 million due to costs incurred upon the initiation of the registration-enabling Phase 2 trial for INBRX-101 for the treatment of emphysema due to AATD, which we initiated during the current year, as well as the progression of our INBRX-109 registration-enabling Phase 2 trial for the treatment of unresectable or metastatic conventional chondrosarcoma. Costs associated with our Phase 1/2 clinical trials for INBRX-105 and INBRX-106 remained consistent in each period;

•contract manufacturing expense increased by $6.8 million due to the nature of the development and manufacturing activities performed during the current period at our CDMO and CRO partners supporting our clinical and preclinical therapeutic candidates, which reflect the stage-specific needs of our programs, including early and late stage drug substance clinical manufacturing, analytical development, QC testing, and stability studies, as well as drug product development, scale-up, robustness studies, and selected BLA-enabling activities;

•personnel-related expense increased by $9.6 million, primarily related to an increase in headcount as a result of a significant expansion of our clinical team, as well as the issuance of additional stock options and the expansion of the bonus eligibility pool during the current year;

•facility and equipment-related expense increased by $0.8 million, which was attributable to an increase in software subscriptions to support research and development activities, in addition to increased repairs and maintenance services; and

•other research and development expense increased by $3.5 million, which was primarily attributable to an increase in travel expenses to clinical and vendor sites, clinical-related consulting expenses, the purchase of lab supplies, and preclinical studies.

G&A Expense

G&A expenses increased by $5.7 million from $15.8 million during the nine months ended September 30, 2022 to $21.5 million during the nine months ended September 30, 2023. The overall increase during the nine months ended September 30, 2023, was primarily due to the following factors:

•personnel-related expenses increased by $4.1 million, related to an increase in headcount primarily due to building out our commercial strategy and medical affairs team, additional stock option grants to employees, and the expansion of the bonus eligibility pool in the current year;

•pre-commercialization expenses increased by $0.8 million, primarily related to increases in consulting services to support our commercial operations business intelligence strategies and our market research expenses related to INBRX-101 and INBRX-109; and

•facility and equipment-related expense increased by $0.5 million, which was primarily attributable to an increase in software subscriptions and IT services related to software implementations.

Other Expense

Interest expense. Interest expense increased by $12.5 million from $11.1 million during the nine months ended September 30, 2022 to $23.6 million during the nine months ended September 30, 2023, all of which relates to interest incurred and the amortization of debt discounts related to the Amended 2020 Loan Agreement. The increase in interest expense is the result of an increase in outstanding principal balance from $170.0 million as of September 30, 2022 to $200.0 million as of September 30, 2023 as well as an increase in our variable interest rate driven by overall market conditions during the nine months ended September 30, 2023. For more information regarding the Amended 2020 Loan Agreement, refer to Note 3 to the condensed consolidated financial statements.

Interest income. During the nine months ended September 30, 2023, we earned $7.2 million of interest income, of which $2.8 million related to interest earned on our sweep and money market account balances and $4.4 million related to the accretion of discounts on investments in debt securities during the period. During the nine months ended September 30, 2022, we earned $0.3 million of interest income. The increase in interest income during the nine months ended September 30, 2023 is the result of higher cash and cash equivalent balances, coupled with rising interest rates, generating higher returns.

Liquidity, Capital Resources and Financial Condition

Sources of Liquidity

To date, sources of capital raised to fund our operations have been comprised of the sale of equity securities, borrowings under the loan and security agreements for gross proceeds of $200.0 million, payments received from commercial partners for licensing rights to our therapeutic candidates under development, grants, and proceeds from the sale and issuance of convertible promissory notes.

Through ~~September~~March 3031, ~~2023~~2024, proceeds from the sale of equity securities as a public company consisted of (i) $136.9 million in gross proceeds from our initial public offering, (ii) $171.4 million in gross proceeds under our Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, and (iii) $200.0 million in gross proceeds from the private placement transaction with certain institutional and other accredited investors, or Purchasers, in which we sold and issued shares of our common stock and, with respect to certain Purchasers, pre-funded warrants to purchase our common stock pursuant to a Securities Purchase Agreement, or the Purchase Agreement. The Purchasers have certain registration rights pursuant to the Purchase Agreement which have been waived until the first business day following December 31, 2023. Sales of our common stock made pursuant to the Sales Agreement have been made under our $400.0 million Shelf Registration on Form S-3ASR, which became automatically effective upon filing on September 3, 2021. As of September 30, 2023, we have used a total of $171.4 million of the $400.0 million under our Shelf Registration, with $228.6 million remaining and available for use.

Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, and (iii) $200.0 million in gross proceeds from the private placement transaction with certain institutional and other accredited investors, or Purchasers, in which we sold and issued shares of our common stock and, with respect to certain Purchasers, pre-funded warrants to purchase our common stock pursuant to a Securities Purchase Agreement, as amended, or the Purchase Agreement. The Purchasers have certain registration rights pursuant to the Purchase Agreement which have been waived after the close of the Merger. Sales of our common stock made pursuant to the Sales Agreement have been made under our $400.0 million Shelf Registration on Form S-3ASR, which became automatically effective upon filing on September 3, 2021. As of March 31, 2024, we have used a total of $171.4 million of the $400.0 million under our Shelf Registration, with $228.6 million remaining and available for use.

Future Funding Requirements

Since our inception, we have devoted substantially all of our efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of our therapeutic candidates, establishing our intellectual property portfolio, developing our commercialization strategy, hiring to support these departments and activities and raising capital to support and expand these activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. Our net loss for the three months ended March 31, 2024 and March 31, 2023 was $78.7 million and $48.9 million, respectively. As of March 31, 2024, we had an accumulated deficit of $692.4 million and cash and cash equivalents of $252.5 million.

34In January 2024, we announced the Merger with Aventis, which, subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals, we currently expect to close during the second quarter of 2024. In connection with the Merger Agreement, we have agreed to various covenants, including, among others, agreement to conduct our business in the ordinary course during the period between the execution of the Merger Agreement and the effective time of the Merger. Outside of certain limited exceptions, we may not take, authorize, commit, resolve, or agree to do certain actions without Aventis’s consent, including, but not limited to:

~~Our~~•acquiring ~~net~~businesses ~~loss for the nine months ended September 30, 2023~~ and ~~September 30,~~disposing ~~2022 was $147.8 million and $104.3 million, respectively. As~~ of ~~September 30,~~significant 2023, we had an accumulated deficit of $520.1 million and cash and cash equivalents of $337.3 million. Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months from the date these condensed consolidated financial statements are issued. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong and we could deplete our capital resources sooner than we expect. assets;

~~The~~•incurring ~~process~~expenditures ofabove ~~conducting~~specified preclinical studies and testing product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. We expect to continue to incur net losses for the foreseeable future until, if ever, we have an approved product and can successfully commercialize it. We expect our research and development expenses to increase as we continue our development of, and seek marketing approvals for, our therapeutic candidates (especially as we move more candidates into later stages of clinical development), and begin to commercialize any approved products, if ever. At this time, we are preparing to proceed with the commercialization of certain of our product candidates, if ever approved. As a result, we will incur significant pre-commercialization expenses in preparation for launch, the outcome of which is uncertain. Additionally, if approved, we will incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. We also expect additional general and administrative expenses as we hire additional personnel and incur increased accounting, audit, legal, regulatory and compliance, investor and public relations expense to support the Company as we continue to expand.thresholds;

•issuing equity;

•issuing debt facilities; and

•repurchasing shares of our outstanding common stock.

We do not believe these restrictions will prevent us from meeting our ongoing costs of operations, working capital needs, or capital expenditure requirements.

Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months from the date these condensed consolidated financial statements are issued. Our forecast of the period through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect.

The process of conducting preclinical studies and testing product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. We expect to continue to incur net losses for the foreseeable future until, if ever, we have an approved product and can successfully commercialize it. We expect our research and development expenses to increase as we continue our development of, and seek marketing approvals for, our therapeutic candidates (especially as we move more candidates into later stages of clinical development), and begin to commercialize any approved products, if ever. At this time, we are preparing to proceed with the commercialization of certain of our product candidates, if ever approved. As a result, we will incur significant pre-commercialization expenses in preparation for launch, the outcome of which is uncertain. Additionally, if approved, we will incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. We also expect additional general and administrative expenses as we hire additional personnel and

incur increased accounting, audit, legal, regulatory and compliance, investor and public relations expense to support our continued expansion.

Until such time we, if ever, can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaborations, strategic transactions, or other similar arrangements and transactions, and from time to time, we engage in discussions with potential acquirers regarding the disposition of one or more of our product candidates. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our intellectual property on less favorable terms than we would otherwise choose. These actions could materially impact our business, results of operations, financial condition, and prospects.

Our future liquidity and capital funding requirements will depend on numerous factors, including:

•the outcome, costs and timing of preclinical studies and clinical trials for our current or future therapeutic candidates;

•whether and when we are able to obtain marketing approval to market any of our therapeutic candidates and the outcome of meetings with applicable regulatory agencies, including the FDA;

•our ability to successfully commercialize any therapeutic candidates that receive marketing approval;

•the emergence and effect of competing or complementary therapeutics or therapeutic candidates;

•our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

•our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel;

•the terms and timing of any strategic licensing, collaboration or other similar agreement that we have established or may establish;

•our ability to repay, refinance or restructure our indebtedness when payment is due, including in the event such indebtedness is accelerated;

•the valuation of our capital stock; and

•the continuing or future effects of a potential economic downturn, geopolitical events, and widespread health events on capital and financial markets.

We do not own or operate manufacturing and testing facilities for the production of any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on a limited number of third-party contract manufacturers for all of our required raw materials, antibodies and other biologics for our preclinical research, clinical trials, and if and when applicable, commercial product, and employ internal resources to manage our manufacturing relationships with these third parties.

Commitments

Our material cash requirements from known contractual and other obligations primarily relate to our lease obligations, debt, and services provided by our third party CROs, and CDMOs.

We have two leases for our laboratory and office space, which expire in 2025, with an option to extend the leases for an additional five years. As of ~~September~~March 3031, ~~2023~~2024, we ~~have~~had future minimum rental payments under these leases of $32.98 million, of which $2.2 million and $10.76 million are current and non-current, respectively. For more information regarding these lease agreements, refer to Note 76 to the condensed consolidated financial statements.

Under the Amended 2020 Loan Agreement, and assuming the Merger is not consummated, we are required to make interest only payments through February 2025, with all principal payments and final fee payments beginning in March 2025 and continuing through the maturity date of January 2027. The interest-only period may be extended an additional twelve months if the Company raises at least $100.0 million in upfront licensing or partnership proceeds by February 2025, upon which principal payments would begin in March 2026. As of September 30, 2023, we have a minimum obligation of $261.8 million of long-term debt, including minimum interest and final fee payments, of which $18.6 million and $243.2 million are current and non-current, respectively. For more information regarding the Amended 2020 Loan Agreement, refer to Note 3 to the condensed consolidated financial statements.

We enter into contracts in the normal course of business with CROs related to our ongoing preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. These contracts are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately $17.4 million in our condensed consolidated balance sheets for expenditures incurred by CROs and CDMOs as of September 30~~, 2023.~~

~~While~~by ~~these~~February ~~contracts are generally cancellable~~2025, ~~some~~upon ~~may~~which ~~contain~~principal ~~specific~~payments ~~activities~~would ~~that~~begin ~~involve~~in ~~one~~March or2026. ~~more~~As ~~noncancellable~~of ~~commitments~~March 31, ~~including minimum purchase commitments~~2024, ~~binding~~we ~~annual~~had ~~forecasts~~a ~~and~~minimum ~~capital~~obligation ~~equipment~~of ~~investments~~$252.6 ~~Additionally,~~million ~~depending on the timing and reasoning~~ of ~~the~~long-term ~~exit~~debt, ~~certain~~including ~~termination~~minimum ~~penalties~~interest ~~may apply~~ and ~~can~~final ~~range~~fee ~~from~~payments, ~~the cost~~ of ~~work~~which ~~performed~~$26.5 tomillion ~~date~~and up$226.1 tomillion ~~twelve~~are ~~months~~current ofand ~~future~~non-current, ~~committed manufacturing costs~~respectively. AsFor ofmore ~~September 30,~~information ~~2023,~~regarding the ~~noncancellable~~Amended ~~portion~~2020 ofLoan ~~these contracts total in aggregate~~Agreement, ~~excluding~~refer ~~amounts~~to ~~recorded~~Note in3 ~~accounts payable and accrued expenses as of this date is approximately $52.5 million. The noncancellable purchase commitments relate~~ to the ~~purchase~~condensed ofconsolidated ~~raw~~financial ~~materials and future contract manufacturing of drug supply for INBRX-101~~statements.

36We enter into contracts in the normal course of business with CROs related to our ongoing preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. These contracts are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately $45.2 million in our condensed consolidated balance sheets for expenditures incurred by CROs and CDMOs as of March 31, 2024.

While these contracts are generally cancellable, some may contain specific activities that involve one or more noncancellable commitments, including minimum purchase commitments, binding annual forecasts and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from the cost of work performed to date up to twelve months of future committed manufacturing costs. As of March 31, 2024, the noncancellable portion of these contracts totaled in aggregate, excluding amounts recorded in accounts payable and accrued expenses as of this date is approximately $44.8 million. The noncancellable purchase commitments relate to the purchase of raw materials and future contract manufacturing of drug supply for INBRX-101.

Cash Flow Summary

The following table sets forth a summary of the net cash flow activity for each of the periods indicated (in thousands):

	NINE MONTHS ENDED SEPTEMBER 30,
	THREE MONTHS ENDED MARCH 31,
	2023		2022
	2024		2023
Net cash used in operating activities	$	(~~136~~63,~~488~~050)	$	(8439,~~701~~944)
Net cash used in investing activities	(1,~~151~~119)		(~~419~~23)
Net cash provided by financing activities	~~201~~38,~~101~~728		~~99,892~~356
Net increase in cash and cash equivalents	$	63,462	$	14,772
Net decrease in cash and cash equivalents	$	(25,441)	$	(39,611)

Operating Activities

Net cash used in operating activities was $~~136~~63.51 million during the ~~nine~~three months ended ~~September~~March 3031, ~~2023~~2024 and consisted primarily of a net loss of $~~147~~78.87 million, adjusted for non-cash items including accretion on our debt discount and the non-cash portion of interest expense related to our debt of $31.72 million, stock-based compensation expense of $186.4 million, depreciation and amortization of $0.94 million and non-cash lease expense of $10.35 million. Changes in operating assets and liabilities also contributed to the cash used in operating activities, primarily related to an increase in prepaid expenses and other current assets of $192.34 million ~~due~~and toan ~~the~~increase ~~prepayment~~in ofother ~~raw~~non-current ~~materials~~assets ~~to one~~ of ~~our CDMO partners during the third quarter of 2023~~$1.4 ~~This~~million ~~was~~due ~~offset~~to inprepayments ~~part~~and byadditional ~~increases~~deposits inwe ~~accrued~~made ~~expenses~~to ~~and~~our ~~other~~CRO ~~current~~partners ~~liabilities~~during ofthe $8quarter.7 ~~million~~Additionally, ~~and~~receivables anincreased ~~increase~~by ~~in accounts payable of~~ $0.86 million ~~due~~as related to ~~the~~interest ~~timing~~income ofearned ~~payments~~in to our ~~CRO~~interest-bearing ~~and~~bank ~~CDMO~~accounts, ~~partners~~while ~~during~~ the ~~period. Additionally, the~~ operating lease liability decreased by $10.45 million as a result of lease payments made throughout the period,. ~~while~~These ~~deferred~~uses ~~revenue~~of ~~decreased~~cash were offset by increases in accrued expenses and other current liabilities of $8.0 million and an increase in accounts payable of $4.21 million due to the ~~recognition~~timing of ~~revenue~~payments ~~under~~to ~~the~~our ~~Chiesi~~CRO ~~Option~~and ~~Agreement~~CDMO ~~upon~~partners ~~Chiesi’s~~during ~~declination~~the ~~of its option~~period.

Net cash used in operating activities was $8439.79 million during the ~~nine~~three months ended ~~September~~March 3031, ~~2022~~2023 and consisted primarily of a net loss of $~~104~~48.39 million, adjusted for non-cash items including accretion on our debt discount and the non-cash portion of interest expense related to our debt of $21.2 million, stock-based compensation expense of $155.16 million, depreciation and amortization of $0.93 million, and non-cash lease expense of $10.24 million. Changes in operating assets and liabilities also contributed to the cash used in operating activities, primarily related to increases in ~~prepaid~~accrued expenses and other current ~~assets~~liabilities of $02.4 million and ~~accrued~~accounts payable of $2.3 million, offset in part by increases in prepaid expenses and other current ~~liabilities~~assets of $52.08 million due to the timing of clinical activity and contract manufacturing work performed by our CDMO partners. ~~These~~during ~~were~~the ~~offset by increases in other non-current assets of $1~~period.3 ~~million relating to deposits paid to one of our CRO partners.~~ Additionally, ~~deferred~~the ~~revenue~~operating lease liability decreased by $10.74 million ~~upon~~as ~~the~~a ~~recognition~~result of ~~revenue~~lease ~~under~~payments ~~our~~made ~~option~~throughout ~~and license agreements, and~~ the ~~operating lease liability decreased by $1~~period.~~2 million.~~

Investing Activities

Net cash used in investing activities was $1.21 million and $~~0.4~~23,000 ~~million~~ during the ~~nine~~three months ended ~~September~~March 3031, ~~2023~~2024 and ~~September~~March 3031, ~~2022~~2023, respectively, and was related to capital purchases of laboratory and office equipment.

Financing Activities

Net cash provided by financing activities was $~~201~~38.17 million ~~during~~and ~~the nine months ended September 30, 2023, which consisted primarily of gross proceeds of~~ $~~200.~~0.4 million ~~from~~during the ~~issuance~~three ofmonths ~~our~~ended ~~common~~March ~~stock~~31, 2024 and ~~pre-funded~~March 31, ~~warrants to purchase shares of our common stock in a private placement transaction~~2023, ~~offset in part by the payment of $0.1 million of issuance costs associated with this transaction. Additionally~~respectively, wewhich ~~received~~consisted ~~approximately $1.2 million~~ of proceeds upon the exercise of stock options.

Net cash provided by financing activities was $99.9 million during the nine months ended September 30, 2022 and consisted primarily of approximately $98.9 million in net proceeds from Oxford under the Amended 2020 Loan Agreement upon draw of the Term D loan in February 2022 and the Term E and Term F loans in June 2022. Additionally, we received approximately $1.1 million of proceeds upon the exercise of stock options.

Critical Accounting Estimates and Policies

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements requires us to make estimates and judgements that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Changes in estimates are reflected in reported results for the period in which they become known. Actual results could differ significantly from the estimates made by our management.

There have been no material changes to our critical accounting policies and estimates from those disclosed in our financial statements and the related notes and other financial information included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.32

Recent Accounting Pronouncements

See Note 1 to our condensed consolidated financial statements included elsewhere in this Quarterly Report for a discussion of recent accounting pronouncements and their effect, if any, on us.

3833

Item 3. Quantitative and Qualitative Disclosures about Market Risks.

WeInterest ~~are~~Rate ~~a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.~~Risk

39Our exposure to market risk for changes in interest rates relates primarily to interest earned on our cash and cash equivalents and the interest expense on our variable interest rate debt.

Our cash and cash equivalents consist of cash held in readily available checking and money market accounts. We are exposed to market risk related to fluctuations in interest rates and market prices. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates. However, due to the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition or results of operations.

Our long-term debt outstanding under our loan with Oxford has a variable interest rate based on the Standard Overnight Financing Rate, or SOFR. As of March 31, 2024, we had $200.0 million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement with Oxford. Our term loans bear interest at a rate of the sum of the 1-Month Chicago Mercantile Exchange term secured overnight financing rate, or CME Term SOFR, plus 8.29%. During the three months ended March 31, 2024, the weighted average interest rate on these loans was 13.6%. As of March 31, 2024, an increase or decrease in the Term SOFR rate of 1% would result in a total increase or decrease in our future interest payments of $3.8 million.

Effects of Inflation

Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented.

Foreign Currency Exchange Risk

We are exposed to market risk related to changes in foreign currency exchange rates. We contract with vendors that are located outside the United States, and certain invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. To date, we have not experienced any material effects from foreign currency fluctuations.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were designed and operating effectively at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended ~~September~~March 3031, ~~2023~~2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

4035

Part II — Other Information

Item 1. Legal Proceedings.

WeExcept as disclosed below, we are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.

Item 1A. Risk Factors.

~~There~~Except for the risk factor set forth below, there have been no material changes to the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2022 and in Part II, Item 1A of our Quarterly Report on Form 10-Q for the three months ended March 31,~~ 2023.

~~Item~~We 2.do ~~Unregistered~~not ~~Sales~~track ofour ~~Equity~~research ~~Securities~~and development expenses on a program-by-program basis, ~~Use~~which ofmay ~~Proceeds~~impact our ability to efficiently allocate resources and ~~Issuer~~could ~~Purchases~~adversely ofaffect ~~Equity~~our ~~Securities~~financial condition and results of operation.

In accordance with the applicable accounting and regulatory requirements, we track all research and development expenses in the aggregate and do not measure or track such expenses on a program-by-program basis. As a result, we evaluate the effectiveness of any particular research and development expense using qualitative metrics such as patient data and discussions with our employees overseeing the particular program. Our approach to research and development expenses may limit our ability to accurately assess the cost-effectiveness and progress of individual programs, which could impact our strategic decision-making process. For instance, if our qualitative observations are inaccurate, we may continue to allocate resources to a program that is not cost-effective or underperforming, or conversely, we may underfund a program that could potentially yield significant returns. This could result in inefficient use of our resources and potentially impact our financial condition and results of operations. Moreover, our approach to tracking research and development expenses could potentially impact our ability to attract investors who scrutinize the allocation of research and development expenses as a measure of a company’s management efficiency and strategic focus. If any such risk were to materialize, it could potentially impact our financial condition, results of operations, and ability to attract investments.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

OnInsider ~~November~~Trading 6, 2023 the Compensation Committee of our Board of Directors approved and adopted the Company’s Clawback Policy, or the Clawback Policy, which was established in accordance with the listing requirements of the Nasdaq Stock Market LLC. The Clawback Policy provides for the recovery or “clawback” of certain erroneously awarded incentive-based compensation in the event that the Company is required to prepare an accounting restatement. The Clawback Policy is effective as of October 2, 2023. The foregoing description of the material terms of Clawback Policy is qualified in its entirety by reference to the full text of the Clawback Policy, which is filed as Exhibit 10.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference.Arrangements

41During the quarter ended March 31, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits.

(a) Exhibits.

Exhibit No.

Description of Exhibit

Filed Herewith

Form

Incorporated By Reference File No.

Date Filed

4.1

Form of Pre-Funded Warrant to Purchase Common Stock.

8-K

001-39452

8/29/2023

2.1^

Agreement and Plan of Merger, dated as of January 22, 2024, by and among Inhibrx, Inc., Aventis Inc., and Art Acquisition Sub, Inc.

8-K

001-39452

1/23/2024

10.1^

Form of Securities Purchase Agreement.

8-K

001-39452

8/29/2023

2.2^

Separation and Distribution Agreement, dated as of January 22, 2024, by and among Inhibrx, Inc., Ibex SpinCo, Inc., and Aventis Inc.

8-K

001-39452

1/23/2024

10.2

Inhibrx, Inc. Clawback Policy

4.1

Amendment to Warrants to Purchase Stock, dated January 22, 2024, by and between Inhibrx, Inc. and Oxford Finance LLC.

8-K

001-39452

1/23/2024

4.2

Form of Agreement to Pre-Funded Warrant to Purchase Common Stock and Securities Purchase Agreement, dated January 22, 2024, by and between Inhibrx, Inc. and each holder of the Private Placement Warrants party thereto

8-K

001-39452

1/23/2024

10.1

Termination Agreement, dated February 26, 2024, by and between the Registrant and Elpiscience Biopharmaceuticals, Inc.

10-K

001-39452

2/28/2024

31.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document contained in Exhibit 101

^ Certain ~~schedules~~exhibits toand ~~this~~schedules ~~exhibit~~ have been omitted pursuant to Item 601(ab)(52) of Regulation S-K. ~~Copies~~The ofCompany agrees to furnish supplementally to the ~~omitted~~SEC ~~schedules~~a ~~will~~copy beof ~~furnished~~any toomitted ~~the~~exhibits ~~SEC~~or schedules upon request.

* This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

4237

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						INHIBRX, INC.
Date: November 9, 2023						/s/ Mark P. Lappe
Date: May 9, 2024						/s/ Mark P. Lappe
						Mark P. Lappe
						Chief Executive Officer and Chairman
						(Principal Executive Officer)
Date: November 9, 2023						/s/ Kelly D. Deck
Date: May 9, 2024						/s/ Kelly D. Deck
						Kelly D. Deck, C.P.A.
						Chief Financial Officer
						(Principal Financial and Accounting Officer)

4338

Filing Compare · Inhibrx, Inc.